Intuitive Surgical (ISRG) 10-Q22 Jul 222022 Q2 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2022	Jul. 19, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	000-30713
Entity Registrant Name	Intuitive Surgical, Inc.
State or Other Jurisdiction of Incorporation or Organization	DE
I.R.S. Employer Identification No.	77-0416458
Entity Address, Address Line One	1020 Kifer Road
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94086
City Area Code	408
Local Phone Number	523-2100
Title of each class	Common Stock, par value $0.001 per share
Trading Symbol(s)	ISRG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		357,111,192
Entity Central Index Key	0001035267
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and Cash Equivalents	$ 1,536.1	$ 1,290.9
Short-term investments	2,901.3	2,913.1
Accounts receivable, net	838.5	782.7
Inventory	724	587.1
Prepaids and other current assets	292.6	271.1
Total current assets	6,292.5	5,844.9
Property, plant, and equipment, net	2,109.3	1,876.4
Long-term investments	3,738	4,415.5
Deferred tax assets	515.9	441.4
Intangible and other assets, net	700.4	633.2
Goodwill	349.1	343.6
Total assets	13,705.2	13,555
Current liabilities:
Accounts payable	149.7	121.2
Accrued compensation and employee benefits	278.6	350.1
Deferred revenue	376.3	377.2
Other accrued liabilities	370.4	301.3
Total current liabilities	1,175	1,149.8
Other long-term liabilities	447.8	453.7
Total liabilities	1,622.8	1,603.5
Contingencies (Note 8)
Stockholders’ equity:
Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; zero shares issued and outstanding as of June 30, 2022, and December 31, 2021	0	0
Common stock, 600.0 shares authorized, $0.001 par value, 357.1 shares and 357.7 shares issued and outstanding as of June 30, 2022, and December 31, 2021, respectively	0.4	0.4
Additional paid-in capital	7,484	7,164
Retained earnings	4,682.8	4,760.9
Accumulated other comprehensive income (loss)	(144.2)	(24.2)
Total Intuitive Surgical, Inc. stockholders’ equity	12,023	11,901.1
Noncontrolling interest in joint venture	59.4	50.4
Total stockholders’ equity	12,082.4	11,951.5
Total liabilities and stockholders’ equity	$ 13,705.2	$ 13,555

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	2,500,000	2,500,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	357,100,000	357,700,000
Common stock, shares outstanding (in shares)	357,100,000	357,700,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 1,522.1	$ 1,464	$ 3,009.8	$ 2,756.1
Cost of revenue:
Total cost of revenue	498.8	440.3	976.8	829.8
Gross profit	1,023.3	1,023.7	2,033	1,926.3
Operating expenses:
Selling, general and administrative	418.4	350.2	809.5	676.2
Research and development	207.3	162.3	417.8	322.1
Total operating expenses	625.7	512.5	1,227.3	998.3
Income from operations	397.6	511.2	805.7	928
Interest and other income, net	9.3	15	3.6	47
Income before taxes	406.9	526.2	809.3	975
Income tax expense	93.3	3.2	126.3	16.8
Net income	313.6	523	683	958.2
Less: net income attributable to noncontrolling interest in joint venture	5.8	5.8	9.6	14.7
Net income attributable to Intuitive Surgical, Inc.	$ 307.8	$ 517.2	$ 673.4	$ 943.5
Net income per share attributable to Intuitive Surgical, Inc.:
Basic (in dollars per share)	$ 0.86	$ 1.45	$ 1.88	$ 2.66
Diluted (in dollars per share)	$ 0.85	$ 1.42	$ 1.84	$ 2.59
Shares used in computing net income per share attributable to Intuitive Surgical, Inc.:
Basic (in shares)	358.1	355.7	358.2	355
Diluted (in shares)	363.9	364.9	365.3	364.5
Other comprehensive loss, net of tax:
Change in unrealized gains (losses) on hedge instruments	$ 4.4	$ (0.1)	$ 5.4	$ 6
Change in unrealized losses on available-for-sale securities	(33.4)	(6)	(124.1)	(16)
Change in foreign currency translation gains (losses)	(5.5)	4.4	(2)	(5.1)
Change in prior service cost for employee benefit plans	0	0.1	0.1	0.2
Other comprehensive loss	(34.5)	(1.6)	(120.6)	(14.9)
Total comprehensive income	279.1	521.4	562.4	943.3
Less: comprehensive income attributable to noncontrolling interest	4.8	5.3	9	14.4
Total comprehensive income attributable to Intuitive Surgical, Inc.	274.3	516.1	553.4	928.9
Corporate Joint Venture
Operating expenses:
Less: net income attributable to noncontrolling interest in joint venture	5.8	5.8	9.6	14.7
Product
Revenue:
Total revenue	1,270.4	1,236	2,508.8	2,310.6
Cost of revenue:
Total cost of revenue	421	374	818.3	693.3
Service
Revenue:
Total revenue	251.7	228	501	445.5
Cost of revenue:
Total cost of revenue	$ 77.8	$ 66.3	$ 158.5	$ 136.5

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net income	$ 683	$ 958.2
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and loss on disposal of property, plant, and equipment	157.5	132.8
Amortization of intangible assets	12.3	14.5
Gain on sale of business	(3.8)	0
Loss (gain) on investments, accretion, and amortization, net	33.8	(4.3)
Deferred income taxes	(40.1)	(24)
Share-based compensation expense	247.5	211.3
Amortization of contract acquisition assets	13.6	10
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable	(56)	(59.6)
Inventory	(245.5)	(92.4)
Prepaids and other assets	(90.1)	(177)
Accounts payable	12.4	38.2
Accrued compensation and employee benefits	(71.5)	19
Deferred revenue	(3.1)	10.6
Other liabilities	19.7	(17)
Net cash provided by operating activities	669.7	1,020.3
Investing activities:
Purchase of investments	(1,376.2)	(3,507.7)
Proceeds from sales of investments	0	72.1
Proceeds from maturities of investments	1,865.1	2,596.9
Purchase of property, plant, and equipment and intellectual property	(225.6)	(134.3)
Acquisition of businesses, net of cash, and other investing activities	(11.8)	(8.7)
Net cash provided by (used in) investing activities	251.5	(981.7)
Financing activities:
Proceeds from issuance of common stock relating to employee stock plans	106.6	153.7
Taxes paid related to net share settlement of equity awards	(179)	(187.9)
Repurchase of common stock	(606.6)	0
Payment of deferred purchase consideration	(3)	(9.7)
Net cash used in financing activities	(682)	(43.9)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	6	(2.6)
Net increase (decrease) in cash, cash equivalents, and restricted cash	245.2	(7.9)
Cash, cash equivalents, and restricted cash, beginning of period	1,306	1,638.5
Cash, cash equivalents, and restricted cash, end of period	$ 1,551.2	$ 1,630.6

DESCRIPTION OF THE BUSINESS

DESCRIPTION OF THE BUSINESS	6 Months Ended
DESCRIPTION OF THE BUSINESS	Jun. 30, 2022
Accounting Policies [Abstract]
DESCRIPTION OF THE BUSINESS	DESCRIPTION OF THE BUSINESS Intuitive Surgical, Inc. (“Intuitive” or the “Company”) develops, manufactures, and markets the da Vinci ® Surgical System and the Ion ® endoluminal system. The Company’s products and related services enable physicians and healthcare providers to improve the quality of and access to minimally invasive care. The systems consist of a surgeon console or consoles, a patient-side cart, a high-performance vision system, and proprietary instruments and accessories.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Jun. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) of Intuitive Surgical, Inc. and its wholly and majority-owned subsidiaries have been prepared on a consistent basis with the audited Consolidated Financial Statements for the fiscal year ended December 31, 2021, and include all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, omit certain information and footnote disclosure necessary to present the Financial Statements in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”). These Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 3, 2022. The results of operations for the first six months of 2022 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods. The Financial Statements include the results and balances of the Company’s majority-owned joint venture (“Joint Venture”) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”). Chindex Medical Limited (“Chindex”), a subsidiary of Fosun Pharma, has been its distribution partner for da Vinci Surgical Systems in China. The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the consolidated stockholders’ equity. The noncontrolling interest’s share of the earnings in the Joint Venture is presented separately in the Condensed Consolidated Statements of Comprehensive Income. Common Stock Split Shares issued pursuant to the three-for-one stock split (the “Stock Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share, were distributed on October 4, 2021, to stockholders of record as of September 27, 2021. All share and per-share information presented in the Financial Statements have been retroactively adjusted to reflect the Stock Split. Risks and Uncertainties The Company’s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments of outstanding receivables, supply chain disruptions, including shortages and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. In particular, the Company has experienced increased difficulties in obtaining a sufficient supply of a number of component materials used in its products, such as semiconductor components as well as a range of other materials including, but not limited to, metals and polymers, as global supply has become significantly constrained due to increased demand for certain materials. Additionally, prices of such materials have increased due to the increased demand and supply shortage. With rising interest rates, access to credit may become more difficult, and any insolvency of the Company’s key suppliers, including sole-source suppliers, may exacerbate current supply chain challenges. The Company is engaged in activities to seek to mitigate supply disruptions by, for example, increasing its communications with its suppliers and modifying its purchase order coverage and inventory levels. However, the global supply chain shortages are likely to remain a challenge for the foreseeable future. The Company has also experienced challenges in logistics, as certain shipping routes have been impacted by port closures. Such global shortages in important components and logistics challenges have resulted in, and will continue to cause, inflationary cost pressure in the Company’s supply chain. To date, the inflationary cost pressure has been more pronounced in the Company’s logistics costs, but these supply chain challenges have not materially impacted the Company’s results of operations or ability to deliver products and services to its customers. However, if shortages in important supply chain materials in the semiconductor or other markets or logistics challenges continue, the Company could fail to meet product demand, which could result in deferred or cancelled procedures. Additionally, if inflationary pressures in logistics or component costs persist, the Company may not be able to quickly or easily adjust pricing, reduce costs, or implement countermeasures. Additionally, there is uncertainty surrounding the impact of any monetary policy changes taken by the U.S. Federal Reserve and other central banks to address the structural risks associated with inflation. Increased labor shortages globally, including staff burnout and attrition, could also impact the Company’s ability to hire and retain personnel critical to its manufacturing, logistics, and commercial operations. The Company is also highly dependent on the principal members of its management and scientific staff. Attracting and retaining qualified personnel is critical to its success, and competition for them has become more intense. The loss of critical members of the Company’s team, or its inability to attract and retain qualified personnel, could significantly harm its operations, business, and ability to compete. Hospitals are also experiencing staffing shortages and supply chain issues that could affect their ability to provide patient care. Additionally, hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs, rising interest rates make access to credit more expensive, unrealized losses decrease available cash reserves, and fiscal stimulus programs enacted during the COVID-19 pandemic wind down. To the extent macroeconomic conditions remain challenging, it is likely that hospitals’ spend on capital equipment will be adversely impacted. In addition, as competition progresses in various markets, longer selling cycles and pricing pressures are likely to result. As of the date of issuance of these Financial Statements, the extent to which these macroeconomic factors may materially adversely affect the Company’s financial condition, liquidity, or results of operations is uncertain. The Company is also subject to additional risks and uncertainties due to the ongoing COVID-19 pandemic. The extent of the impact on the Company’s business is highly uncertain and difficult to predict. In certain regions, the Company’s customers continue to divert resources to treat COVID-19 patients and defer some elective surgical procedures, both of which may impact the Company’s customers’ ability to meet their obligations, including to the Company. Furthermore, economies worldwide have been negatively impacted by the COVID-19 pandemic, and it is possible that the impact could cause an extended local and/or global economic recession. Such economic disruption could have a material adverse effect on the Company’s business as hospitals curtail and reduce capital and overall spending. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and their economies. However, the magnitude and overall effectiveness of these actions remains uncertain. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, all of which are uncertain and cannot be predicted. Recently Adopted Accounting Pronouncements Business Combinations In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company has early adopted ASU 2021-08 as of January 1, 2022, on a prospective basis. The impact of the adoption of ASU 2021-08 had an immaterial impact on the Company’s Financial Statements in the six months ended June 30, 2022. Recent Accounting Pronouncements Troubled Debt Restructurings and Vintage Disclosures In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures (“ASU 2022-02”), which eliminates the accounting guidance for troubled debt restructurings by creditors while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. Additionally, the standard requires disclosure of current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic ASC 326-20, Financial Instruments-Credit Losses-Measured at Amortized Cost . The standard will become effective for the Company beginning January 1, 2023, and should be applied prospectively. The adoption of ASU 2022-02 is not expected to have a material impact on the Company’s future Financial Statements. Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), which applies to all equity securities measured at fair value that are subject to contractual sale restrictions. This change prohibits entities from taking into account contractual restrictions on the sale of equity securities when estimating fair value and introduces required disclosures for such transactions. The standard will become effective for the Company beginning January 1, 2024, and should be applied prospectively. Early adoption is permitted. The adoption of ASU 2022-03 is not expected to have a material impact on the Company’s future Financial Statements. Significant Accounting Policies There have been no new or material changes to the significant accounting policies discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, that are of significance, or potential significance, to the Company.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	6 Months Ended
FINANCIAL INSTRUMENTS	Jun. 30, 2022
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS Cash, Cash Equivalents, and Investments The following tables summarize the Company’s cash and available-for-sale marketable securities’ amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit loss, and fair value by significant investment category reported as cash and cash equivalents, short-term investments, or long-term investments as of June 30, 2022 and December 31, 2021 (in millions): Reported as: Amortized Gross Gross Allowance for Credit Loss Fair Cash and Short- Long- June 30, 2022 Cash $ 532.7 $ — $ — $ — $ 532.7 $ 532.7 $ — $ — Level 1: Money market funds 1,003.4 — — — 1,003.4 1,003.4 — — U.S. treasuries 3,330.1 — (89.6) — 3,240.5 — 1,447.1 1,793.4 Subtotal 4,333.5 — (89.6) — 4,243.9 1,003.4 1,447.1 1,793.4 Level 2: Commercial paper 310.6 — — — 310.6 — 310.6 — Corporate debt securities 2,472.2 — (69.1) (1.1) 2,402.0 — 927.5 1,474.5 U.S. government agencies 522.9 0.1 (16.7) — 506.3 — 149.9 356.4 Municipal securities 185.2 — (5.3) — 179.9 — 66.2 113.7 Subtotal 3,490.9 0.1 (91.1) (1.1) 3,398.8 — 1,454.2 1,944.6 Total assets measured at fair value $ 8,357.1 $ 0.1 $ (180.7) $ (1.1) $ 8,175.4 $ 1,536.1 $ 2,901.3 $ 3,738.0 Reported as: Amortized Gross Gross Allowance for Credit Loss Fair Cash and Short- Long- December 31, 2021 Cash $ 572.3 $ — $ — $ — $ 572.3 $ 572.3 $ — $ — Level 1: Money market funds 696.6 — — — 696.6 696.6 — — U.S. treasuries 3,429.1 6.3 (15.4) — 3,420.0 17.0 1,100.3 2,302.7 Subtotal 4,125.7 6.3 (15.4) — 4,116.6 713.6 1,100.3 2,302.7 Level 2: Commercial paper 717.7 — — — 717.7 — 717.7 — Corporate debt securities 2,485.6 2.7 (11.9) — 2,476.4 5.0 886.7 1,584.7 U.S. government agencies 526.1 0.2 (2.9) — 523.4 — 137.8 385.6 Municipal securities 213.4 0.7 (1.0) — 213.1 — 70.6 142.5 Subtotal 3,942.8 3.6 (15.8) — 3,930.6 5.0 1,812.8 2,112.8 Total assets measured at fair value $ 8,640.8 $ 9.9 $ (31.2) $ — $ 8,619.5 $ 1,290.9 $ 2,913.1 $ 4,415.5 The following table summarizes the contractual maturities of the Company’s cash equivalents and available-for-sale investments (excluding cash and money market funds), as of June 30, 2022 (in millions): Amortized Fair Mature in less than one year $ 2,930.9 $ 2,901.3 Mature in one to five years 3,890.1 3,738.0 Total $ 6,821.0 $ 6,639.3 Actual maturities may differ from contractual maturities, because certain borrowers have the right to call or prepay certain obligations. Realized gains and losses recognized on the sale of investments were not material for any of the periods presented. The following tables present the breakdown of the available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category, as of June 30, 2022, and December 31, 2021 (in millions): June 30, 2022 Less than 12 months More than 12 months Total Fair Gross Fair Gross Fair Gross U.S. treasuries $ 2,882.3 $ (74.6) $ 327.0 $ (15.0) $ 3,209.3 $ (89.6) Commercial paper 3.0 — — — 3.0 — Corporate debt securities 1,917.7 (59.5) 182.3 (9.6) 2,100.0 (69.1) U.S. government agencies 479.8 (15.7) 16.5 (1.0) 496.3 (16.7) Municipal securities 130.0 (3.5) 41.5 (1.8) 171.5 (5.3) Total $ 5,412.8 $ (153.3) $ 567.3 $ (27.4) $ 5,980.1 $ (180.7) December 31, 2021 Less than 12 months More than 12 months Total Fair Gross Fair Gross Fair Gross U.S. treasuries $ 2,596.3 $ (15.4) $ — $ — $ 2,596.3 $ (15.4) Commercial paper 4.0 — — — 4.0 — Corporate debt securities 1,687.9 (11.9) — — 1,687.9 (11.9) U.S. government agencies 412.5 (2.9) — — 412.5 (2.9) Municipal securities 156.0 (1.0) — — 156.0 (1.0) Total $ 4,856.7 $ (31.2) $ — $ — $ 4,856.7 $ (31.2) Equity Investments The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company generally recognizes equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments (in millions): Reported as: December 31, 2021 Carrying Value Changes in Fair Value (1) Purchases/Sales June 30, 2022 Carrying Value Prepaids and other current assets Intangible and other assets, net Equity investments with readily determinable value (Level 1) $ 26.9 $ (18.3) $ — $ 8.6 $ 8.6 $ — Equity investments without readily determinable value (Level 2) $ 15.6 $ 0.2 $ 20.5 $ 36.3 $ — $ 36.3 (1) Recorded in Interest and other income (expense), net. Foreign Currency Derivatives The objective of the Company’s hedging program is to mitigate the impact of changes in currency exchange rates on net cash flow from foreign currency-denominated sales, expenses, intercompany balances, and other monetary assets or liabilities denominated in currencies other than the U.S. dollar (“USD”). The terms of the Company’s derivative contracts are generally twelve months or shorter. The derivative assets and liabilities are measured using Level 2 fair value inputs. Cash Flow Hedges The Company enters into currency forward contracts as cash flow hedges to hedge certain forecasted revenue transactions denominated in currencies other than the USD, primarily the Euro (“EUR”), the British Pound (“GBP”), the Japanese Yen (“JPY”), the Korean Won (“KRW”), and the New Taiwan Dollar (“TWD”). The Company also enters into currency forward contracts as cash flow hedges to hedge certain forecasted expense transactions denominated in EUR and the Swiss Franc (“CHF”). For these derivatives, the Company reports the unrealized after-tax gain or loss from the hedge as a component of accumulated other comprehensive income/(loss) in stockholders’ equity and reclassifies the amount into earnings in the same period in which the hedged transaction affects earnings. The amounts reclassified to revenue and expenses related to the hedged transactions and the ineffective portions of cash flow hedges were not material for the periods presented. Other Derivatives Not Designated as Hedging Instruments Other derivatives not designated as hedging instruments consist primarily of forward contracts that the Company uses to hedge intercompany balances and other monetary assets or liabilities denominated in currencies other than the USD, primarily the EUR, GBP, JPY, KRW, CHF, TWD, Indian Rupee ("INR"), Mexican Peso ("MXN"), and Chinese Yuan ("CNY"). These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Recognized gains/(losses) in Interest and other income (expense), net $ 21.9 $ (4.0) $ 28.7 $ 7.4 Foreign exchange gains/(losses) related to balance sheet re-measurement $ (28.8) $ 5.0 $ (38.9) $ (6.0) The notional amounts for derivative instruments provide one measure of the transaction volume. Total gross notional amounts (in USD) for outstanding derivatives and the aggregate gross fair value at the end of each period were as follows (in millions): Derivatives Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments June 30, December 31, June 30, December 31, Notional amounts: Forward contracts $ 204.4 $ 181.2 $ 335.1 $ 318.8 Gross fair value recorded in: Prepaids and other current assets $ 12.3 $ 5.7 $ 12.5 $ 6.9 Other accrued liabilities $ 0.8 $ 0.5 $ 1.1 $ 0.8

BALANCE SHEET DETAILS AND OTHER

BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION	6 Months Ended
BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION	BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION Balance Sheet Details The following tables provide details of selected balance sheet line items (in millions): As of Inventory June 30, December 31, Raw materials $ 294.9 $ 214.6 Work-in-process 117.4 96.4 Finished goods 311.7 276.1 Total inventory $ 724.0 $ 587.1 As of Prepaids and other current assets June 30, December 31, Prepaid taxes $ 20.7 $ 4.3 Equity investments 8.6 26.9 Net investment in sales-type leases–short-term 116.5 110.3 Other prepaids and other current assets 146.8 129.6 Total prepaids and other current assets $ 292.6 $ 271.1 As of Other accrued liabilities–short-term June 30, December 31, Taxes payable $ 40.8 $ 54.1 Current portion of deferred and contingent purchase consideration 7.2 12.0 Accrued construction-related capital expenditures 72.1 23.1 Other accrued liabilities 250.3 212.1 Total other accrued liabilities–short-term $ 370.4 $ 301.3 As of Other long-term liabilities June 30, December 31, Income taxes–long-term $ 288.2 $ 316.6 Deferred revenue–long-term 37.4 36.8 Other long-term liabilities 122.2 100.3 Total other long-term liabilities $ 447.8 $ 453.7 Supplemental Cash Flow Information The following table provides supplemental non-cash investing and financing activities (in millions): Six Months Ended June 30, 2022 2021 Equipment transfers, including operating lease assets, from inventory to property, plant, and equipment $ 122.7 $ 139.4 Acquisition of property, plant, and equipment in accounts payable and accrued liabilities $ 95.8 $ 14.3

REVENUE AND CONTRACT ACQUISITIO

REVENUE AND CONTRACT ACQUISITION COSTS	6 Months Ended
REVENUE AND CONTRACT ACQUISITION COSTS	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
REVENUE AND CONTRACT ACQUISITION COSTS	REVENUE AND CONTRACT ACQUISITION COSTS The following table presents revenue disaggregated by types and geography (in millions): Three Months Ended June 30, Six Months Ended June 30, U.S. 2022 2021 2022 2021 Instruments and accessories $ 625.1 $ 577.5 $ 1,175.7 $ 1,078.3 Systems 218.0 277.6 466.3 480.3 Services 168.0 150.7 333.9 294.7 Total U.S. revenue $ 1,011.1 $ 1,005.8 $ 1,975.9 $ 1,853.3 Outside of U.S. (“OUS”) Instruments and accessories $ 270.2 $ 218.9 $ 529.9 $ 424.0 Systems 157.1 162.0 336.9 328.0 Services 83.7 77.3 167.1 150.8 Total OUS revenue $ 511.0 $ 458.2 $ 1,033.9 $ 902.8 Total Instruments and accessories $ 895.3 $ 796.4 $ 1,705.6 $ 1,502.3 Systems 375.1 439.6 803.2 808.3 Services 251.7 228.0 501.0 445.5 Total revenue $ 1,522.1 $ 1,464.0 $ 3,009.8 $ 2,756.1 Remaining Performance Obligations The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which revenue has not yet been recognized. A significant portion of these performance obligations relate to service obligations in the Company’s system sale and lease arrangements that will be satisfied and recognized as revenue in future periods. The transaction price allocated to the remaining performance obligations wa s $1.83 billion as of June 30, 2022. The remaining performance obligations are expected to be satisfied over the term of the system sale, lease, and service arrangements, which are generally up to 5 years. Contract Assets and Liabilities The following information summarizes the Company’s contract assets and liabilities (in millions): As of June 30, 2022 December 31, 2021 Contract assets $ 50.6 $ 46.9 Deferred revenue $ 413.7 $ 414.0 The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms in the arrangements. Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented. During the three and six months ended June 30, 2022, the Company recognized $125 million and $318 million of revenue, respectively, that was included in the deferred revenue balance as of December 31, 2021. During the three and six months ended June 30, 2021, the Company recognized $99 million and $250 million of revenue, respectively, that was included in the deferred revenue balance as of December 31, 2020. Intuitive System Leasing The following table presents revenue from Intuitive System Leasing arrangements (in millions): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales-type lease revenue $ 50.1 $ 84.0 $ 85.7 $ 101.3 Operating lease revenue* $ 93.0 $ 67.3 $ 176.2 $ 126.3 *Variable lease revenue relating to usage-based arrangements included within operating lease revenue $ 33.6 $ 21.0 $ 58.5 $ 34.5

LEASES

LEASES	6 Months Ended
LEASES	Jun. 30, 2022
Leases [Abstract]
LEASES	LEASES Lessor Information Sales-type Leases. Lease receivables relating to sales-type lease arrangements are presented on the Condensed Consolidated Balance Sheets as follows (in millions): As of June 30, 2022 December 31, 2021 Gross lease receivables $ 433.3 $ 404.0 Unearned income (13.5) (11.4) Subtotal 419.8 392.6 Allowance for credit loss (3.4) (3.6) Net investment in sales-type leases $ 416.4 $ 389.0 Reported as: Prepaids and other current assets $ 116.5 $ 110.3 Intangible and other assets, net 299.9 278.7 Total, net $ 416.4 $ 389.0 Contractual maturities of gross lease receivables as of June 30, 2022, are as follows (in millions): Fiscal Year Amount Remainder of 2022 $ 63.6 2023 121.7 2024 108.3 2025 78.1 2026 46.8 2027 and thereafter 14.8 Total $ 433.3 The Company enters into sales-type leases with certain qualified customers to purchase its systems. Sales-type leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The allowance for loan loss is based on the Company’s assessment of current expected lifetime losses on lease receivables. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the lease receivable balances, and current economic conditions that may affect a customer’s ability to pay. Lease receivables are considered past due 90 days after invoice. The Company manages the credit risk in net investment in sales-type leases using a number of factors, including, but not limited to the following: size of operations; profitability, liquidity, and debt ratios; payment history; and past due amounts. The Company also uses credit scores obtained from external providers as a key indicator for the purposes of determining credit quality. The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of June 30, 2022 (in millions): 2022 2021 2020 2019 2018 Prior Net Investment Credit Rating: High $ 47.6 $ 119.3 $ 61.8 $ 20.8 $ 3.4 $ 1.7 $ 254.6 Moderate 47.8 65.2 31.4 7.2 5.3 0.4 157.3 Low — 0.8 3.7 2.1 1.2 0.1 7.9 Total $ 95.4 $ 185.3 $ 96.9 $ 30.1 $ 9.9 $ 2.2 $ 419.8 For the three and six months ended June 30, 2022, and 2021, credit losses related to net investment in sales-type leases were not material.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
GOODWILL AND INTANGIBLE ASSETS	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Acquisitions There were no material acquisitions for the six months ended June 30, 2022, and 2021. Goodwill The following table summarizes the changes in the carrying amount of goodwill (in millions): Amount Balance as of December 31, 2021 $ 343.6 Acquisition activity 6.5 Translation and other (1.0) Balance as of June 30, 2022 $ 349.1 Intangible Assets The following table summarizes the components of gross intangible assets, accumulated amortization, and net intangible asset balances as of June 30, 2022, and December 31, 2021 (in millions): June 30, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Patents and developed technology $ 219.3 $ (180.6) $ 38.7 $ 219.3 $ (173.2) $ 46.1 Distribution rights and others 31.5 (21.5) 10.0 26.3 (19.4) 6.9 Customer relationships 33.5 (16.0) 17.5 31.8 (14.3) 17.5 Total intangible assets $ 284.3 $ (218.1) $ 66.2 $ 277.4 $ (206.9) $ 70.5 The estimated future amortization expense related to intangible assets as of June 30, 2022, is as follows (in millions): Fiscal Year Amount Remainder of 2022 $ 16.0 2023 19.6 2024 15.6 2025 10.3 2026 3.3 2027 and thereafter 1.4 Total $ 66.2 The preceding expected amortization expense is an estimate. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, measurement-period adjustments to intangible assets, changes in foreign currency exchange rates, impairments of intangible assets, accelerated amortization of intangible assets, and other events.

CONTINGENCIES

CONTINGENCIES	6 Months Ended
CONTINGENCIES	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES From time to time, the Company is involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, intellectual property, insurance, contract disputes, employment, and other matters. Certain of these lawsuits and claims are described in further detail below. It is not possible to predict what the outcome of these matters will be, and the Company cannot guarantee that any resolution will be reached on commercially reasonable terms, if at all. A liability and related charge to earnings are recorded in the Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including the impact of negotiations, settlements, rulings, advice of legal counsel, and other information and events pertaining to each case. Nevertheless, it is possible that additional future legal costs (including settlements, judgments, legal fees, and other related defense costs) could have a material adverse effect on the Company’s business, financial position, and future results of operations. Product Liability Litigation The Company is currently named as a defendant in a number of individual product liability lawsuits filed in various state and federal courts. The plaintiffs generally allege that they or a family member underwent surgical procedures that utilized the da Vinci Surgical System and sustained a variety of personal injuries and, in some cases, death as a result of such surgery. Several of the filed cases have trial dates in the next 12 months. The cases raise a variety of allegations including, to varying degrees, that plaintiffs’ injuries resulted from purported defects in the da Vinci Surgical System and/or failure on the Company’s part to provide adequate training resources to the healthcare professionals who performed plaintiffs’ surgeries. The cases further allege that the Company failed to adequately disclose and/or misrepresented the potential risks and/or benefits of the da Vinci Surgical System. Plaintiffs also assert a variety of causes of action, including, for example, strict liability based on purported design defects, negligence, fraud, breach of express and implied warranties, unjust enrichment, and loss of consortium. Plaintiffs seek recovery for alleged personal injuries and, in many cases, punitive damages. The Company disputes these allegations and is defending against these claims. The Company’s estimate of the anticipated cost of resolving the pending cases is based on negotiations with attorneys for the claimants. The final outcome of the pending lawsuits and claims, and others that might arise, is dependent on many variables that are difficult to predict, and the ultimate cost associated with these product liability lawsuits and claims may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on the Company’s business, financial position, and future results of operations. Although there is a reasonable possibility that a loss in excess of the amount recognized exists, the Company is unable to estimate the possible loss or range of loss in excess of the amount recognized at this time. Patent Litigation On June 30, 2017, Ethicon LLC, Ethicon Endo-Surgery, Inc., and Ethicon US LLC (collectively, “Ethicon”) filed a complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint, which was served on the Company on July 12, 2017, alleges that the Company’s EndoWrist Stapler instruments infringe several of Ethicon’s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,585,658; 8,479,969; 9,113,874; 8,998,058; 8,991,677; 9,084,601; and 8,616,431. A claim construction hearing occurred on October 1, 2018, and the Court issued a scheduling order on December 28, 2018. On March 20, 2019, the Court granted the Company’s Motion to Stay pending an Inter Partes Review to be held at the Patent Trademark and Appeals Board to review patentability of six of the seven patents noted above and vacated the trial date. On August 1, 2019, the Court granted the parties’ joint stipulation to modify the stay in light of Ethicon’s U.S. International Trade Commission (“USITC”) complaint against Intuitive involving U.S. Patent Nos. 8,479,969 and 9,113,874, discussed below. There is currently no trial date scheduled for this matter. On August 27, 2018, Ethicon filed a second complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint alleges that the Company’s SureForm 60 Staplers infringe five of Ethicon’s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,884,369; 7,490,749; 8,602,288; 8,602,287; and 9,326,770. The Company filed an answer denying all claims. On March 19, 2019, Ethicon filed a Motion for Leave to File a First Amended Complaint, removing allegations related to U.S. Patent No. 9,326,770 and adding allegations related to U.S. Patent Nos. 9,844,379 and 8,479,969. On July 17, 2019, the Court entered an order denying the amendment, without prejudice, and granting the parties’ joint stipulation to stay the case in its entirety in light of the USITC investigation involving U.S. Patent Nos. 9,844,369 and 7,490,749, discussed below. There is currently no trial date scheduled for this matter. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from these matters. On May 30, 2019, Ethicon filed a complaint with the USITC, asserting infringement of U.S. Patent Nos. 9,884,369 (“’369”); 7,490,749 (“’749”); 9,844,379 (“’379”); 9,113,874 (“’874”); and 8,479,969 (“’969”). On June 28, 2019, the USITC voted to institute an investigation (No. 337-TA-1167) with respect to the claims in this complaint. The accused products include the Company’s EndoWrist 30, EndoWrist 45, SureForm 45, and SureForm 60 Staplers, as well as the stapler reload cartridges. In March 2020, Ethicon dismissed its claims concerning the ’749 patent. The evidentiary hearing took place in February 2021. On March 26, 2021, the U.S. Patent Trial and Appeal Board (“PTAB”) issued a Final Written Decision in which it found the claims in the ’379 patent asserted against the Company in this USITC proceeding to be invalid. On June 8, 2021, the Chief Administrative Law Judge issued an Initial Determination concluding that (1) the accused products do not infringe the asserted claims in the ’874 or ’969 patents; (2) the asserted claims in the ’874 and ’969 patents are invalid; (3) the accused SureForm staplers and associated reload cartridges infringe two claims of the ’369 patent; (4) the accused SureForm staplers and associated reload cartridges infringe two claims of the ’379 patent; and (5) the Company was estopped from contending that the asserted claims in the ’379 patent are invalid. Ethicon has not challenged the Initial Determination with regard to the findings that absolve Intuitive of any liability regarding the accused EndoWrist staplers and associated reload cartridges. On October 14, 2021, the USITC issued its Opinion in which it made the following rulings: (1) the USITC absolved Intuitive from any liability regarding the ’874, ’969, and ’369 patents; and (2) the USITC found that, while the SureForm staplers and their associated reload cartridges infringe the asserted claims in the ’379 patent, it has suspended the imposition of any remedial order pending an opinion from the U.S. Court of Appeal for the Federal Circuit of whether the Patent and Trademark Office correctly found the asserted claims in this patent to be invalid. On May 23, 2022, the U.S. Court of Appeal for the Federal Circuit affirmed the earlier PTAB Final Written Decision invalidating the asserted claims in the ’379 patent. An adverse ruling on Ethicon’s appeal of the USITC’s Opinion could result in a prohibition on importing the accused SureForm products into the U.S. or necessitating workarounds. Based on currently available information, the Company does not believe that any losses arising from this matter would be material. Commercial Litigation On February 27, 2019, Restore Robotics LLC and Restore Repair LLC (“Restore”) filed a complaint in the Northern District of Florida alleging anti-trust claims against the Company. On May 13, 2019, Restore filed an amended complaint alleging anti-trust claims relating to the da Vinci Surgical System and EndoWrist service, maintenance, and repair processes. On September 16, 2019, the Court partially granted and partially denied the Company’s Motion to Dismiss the amended complaint. On September 30, 2019, the Company filed an answer denying the anti-trust allegations and filed a counterclaim against Restore. The Company filed amended counterclaims after the Court partially granted and partially denied Restore’s Motion to Dismiss the counterclaim. The amended counterclaims allege that Restore violated the Federal Lanham Act, the Federal Computer Fraud and Abuse Act, and Florida’s Deceptive and Unfair Trade Practices Act and that Restore is also liable to the Company for Unfair Competition and Tortious Interference with Contract. On January 7, 2020, the Court denied Restore’s Motion to Dismiss the amended counterclaims. On April 11, 2022, the Court granted in part and denied in part the parties’ Motions for Summary Judgment. Shortly thereafter, Restore’s licensor, Rebotix Repair LLC filed a notice in the related Rebotix action (described below) that it had received an email from the U.S. Food and Drug Administration (“FDA”) confirming that “extending the number of uses and modifying [EndoWrist] instrument[s] with a new chip” constitutes “remanufacturing,” and required 510(k) clearance, which neither Restore nor Rebotix has obtained. In light of this communication with the FDA, on April 13, 2022, the Company filed a Motion for Reconsideration to the Court’s Summary Judgment Order, which the Court denied on May 31, 2022. A trial date has been set for February 6, 2023. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from these matters. On September 28, 2020, Rebotix Repair Inc. (“Rebotix”) filed a complaint in the Middle District of Florida alleging anti-trust claims against the Company relating to EndoWrist service, maintenance, and repair processes. The complaint was formally served on the Company on October 6, 2020. On March 8, 2021, the Court partially granted and partially denied the Company’s Motion to Dismiss the complaint. The Company filed an answer denying the anti-trust allegations and filed counterclaims against Rebotix. The counterclaims allege that Rebotix violated the Federal Lanham Act and Florida’s Deceptive and Unfair Trade Practices Act and that Rebotix is also liable to the Company for Tortious Interference with Contract. Motions for Summary Judgment have been filed by the Company and Rebotix. On April 1, 2022, the Court stayed this case based on Rebotix’s representation that the FDA would soon be issuing a decision on whether Rebotix’s services require 510(k) clearance. On April 11, 2022, Rebotix filed a Notice of FDA Decision, which included correspondence from the FDA concluding that Rebotix’s activities constituted remanufacturing and would require FDA review and clearance. On April 13, 2022, the Court issued an Order directing the parties to confer and file a joint status report by May 4, 2022, on how the FDA’s decision impacts this case and how the parties wish to proceed. On May 4, 2022, the parties filed a joint status report, but the Court has not taken further action since that report was filed. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter. Similar to the claims asserted in the Restore case, on May 10, 2021, Surgical Instrument Service Company, Inc. (“SIS”) filed a complaint in the Northern District of California Court alleging anti-trust claims against the Company relating to EndoWrist service, maintenance, and repair processes. The Court granted in part and denied in part the Company’s Motion to Dismiss, and discovery has commenced. The Company filed an answer denying the anti-trust allegations and filed counterclaims against SIS. The counterclaims allege that SIS violated the Federal Lanham Act, California’s Unfair Competition Law, and California’s False Advertising Law and that SIS is also liable to the Company for Unfair Competition and Tortious Interference with Contract. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter. Three class action complaints were filed against the Company in the Northern District of California Court alleging anti-trust allegations relating to the service and repair of certain instruments manufactured by the Company. A complaint by Larkin Community Hospital was filed on May 20, 2021, a complaint by Franciscan Alliance, Inc. and King County Public Hospital District No. 1 was filed on July 6, 2021, and a complaint by Kaleida Health was filed on July 8, 2021. The Court has consolidated the Franciscan Alliance, Inc. and King County Public Hospital District No. 1 and Kaleida Health cases with the Larkin Community Hospital case, which is now captioned on the Larkin docket as “In Re: da Vinci Surgical Robot Antitrust Litigation.” A Consolidated Amended Class Action Complaint has been filed on behalf of each plaintiff named in the earlier-filed cases. On January 14, 2022, Kaleida Health voluntarily dismissed itself as a party to this case. On January 18, 2022, the Company filed an answer against the plaintiffs in this matter, and discovery has commenced. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from these matters.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
STOCKHOLDERS' EQUITY	Jun. 30, 2022
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Stockholders’ Equity The following tables present the changes in stockholders’ equity (in millions): Three Months Ended June 30, 2022 Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Intuitive Surgical, Inc. Stockholders’ Equity Noncontrolling Interest in Joint Venture Total Stockholders’ Equity Shares Amount Beginning balance 358.9 $ 0.4 $ 7,354.6 $ 4,858.0 $ (110.7) $ 12,102.3 $ 54.6 $ 12,156.9 Issuance of common stock through employee stock plans 0.4 — 26.6 — — 26.6 — 26.6 Shares withheld related to net share settlement of equity awards — — (0.6) (6.2) — (6.8) — (6.8) Share-based compensation expense related to employee stock plans — — 126.7 — — 126.7 — 126.7 Repurchase and retirement of common stock (2.2) — (23.3) (476.8) — (500.1) — (500.1) Net income attributable to Intuitive Surgical, Inc. — — — 307.8 — 307.8 — 307.8 Other comprehensive income (loss) — — — — (33.5) (33.5) (1.0) (34.5) Net income attributable to noncontrolling interest in joint venture — — — — — — 5.8 5.8 Ending balance 357.1 $ 0.4 $ 7,484.0 $ 4,682.8 $ (144.2) $ 12,023.0 $ 59.4 $ 12,082.4 Three Months Ended June 30, 2021 Common Stock Additional Retained Accumulated Total Intuitive Surgical, Inc. Stockholders’ Equity Noncontrolling Interest in Joint Venture Total Stockholders’ Equity Shares Amount Beginning balance 355.2 $ 0.4 $ 6,627.0 $ 3,514.7 $ 11.4 $ 10,153.5 $ 36.7 $ 10,190.2 Issuance of common stock through employee stock plans 1.0 — 69.7 — — 69.7 — 69.7 Shares withheld related to net share settlement of equity awards — — (0.7) (9.2) — (9.9) — (9.9) Share-based compensation expense related to employee stock plans — — 108.1 — — 108.1 — 108.1 Net income attributable to Intuitive Surgical, Inc. — — — 517.2 — 517.2 — 517.2 Other comprehensive income (loss) — — — — (1.1) (1.1) (0.5) (1.6) Net income attributable to noncontrolling interest in joint venture — — — — — — 5.8 5.8 Ending balance 356.2 $ 0.4 $ 6,804.1 $ 4,022.7 $ 10.3 $ 10,837.5 $ 42.0 $ 10,879.5 Six Months Ended June 30, 2022 Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Intuitive Surgical, Inc. Stockholders’ Equity Noncontrolling Interest in Joint Venture Total Stockholders’ Equity Shares Amount Beginning balance 357.7 $ 0.4 $ 7,164.0 $ 4,760.9 $ (24.2) $ 11,901.1 $ 50.4 $ 11,951.5 Issuance of common stock through employee stock plans 2.6 — 106.6 — — 106.6 — 106.6 Shares withheld related to net share settlement of equity awards (0.6) — (6.7) (172.3) — (179.0) — (179.0) Share-based compensation expense related to employee stock plans — — 247.5 — — 247.5 — 247.5 Repurchase and retirement of common stock (2.6) — (27.4) (579.2) — (606.6) — (606.6) Net income attributable to Intuitive Surgical, Inc. — — — 673.4 — 673.4 — 673.4 Other comprehensive income (loss) — — — — (120.0) (120.0) (0.6) (120.6) Net income attributable to noncontrolling interest in joint venture — — — — — — 9.6 9.6 Ending balance 357.1 $ 0.4 $ 7,484.0 $ 4,682.8 $ (144.2) $ 12,023.0 $ 59.4 $ 12,082.4 Six Months Ended June 30, 2021 Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Intuitive Surgical, Inc. Stockholders’ Equity Noncontrolling Interest in Joint Venture Total Stockholders’ Equity Shares Amount Beginning balance 353.1 $ 0.4 $ 6,444.9 $ 3,261.3 $ 24.9 $ 9,731.5 $ 27.6 $ 9,759.1 Issuance of common stock through employee stock plans 3.8 — 153.7 — — 153.7 — 153.7 Shares withheld related to net share settlement of equity awards (0.7) — (5.8) (182.1) — (187.9) — (187.9) Share-based compensation expense related to employee stock plans — — 211.3 — — 211.3 — 211.3 Net income attributable to Intuitive Surgical, Inc. — — — 943.5 — 943.5 — 943.5 Other comprehensive income (loss) — — — — (14.6) (14.6) (0.3) (14.9) Net income attributable to noncontrolling interest in joint venture — — — — — — 14.7 14.7 Ending balance 356.2 $ 0.4 $ 6,804.1 $ 4,022.7 $ 10.3 $ 10,837.5 $ 42.0 $ 10,879.5 Stock Repurchase Program The Company’s Board of Directors (the “Board”) has previously authorized an aggregate of $7.5 billion of funding for the Company’s common stock repurchase program (the “Repurchase Program”) since its establishment in March 2009. The most recent authorization occurred in January 2019 when the Board increased the authorized amount available under the Repurchase Program to $2.0 billion. As of June 30, 2022, the remaining amount of share repurchases authorized by the Board was $1.0 billion. On July 20, 2022, the Board increased the authorized amount available under the Repurchase Program to an aggregate of $3.5 billion, including amounts remaining under previous authorization. The following table provides share repurchase activities (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Shares repurchased 2.2 — 2.6 — Average price per share $ 224.4 $ — $ 231.0 $ — Value of shares repurchased $ 500.1 $ — $ 606.6 $ — Accumulated Other Comprehensive Income (Loss), Net of Tax, Attributable to Intuitive Surgical, Inc. The components of accumulated other comprehensive income (loss), net of tax, attributable to Intuitive Surgical, Inc. are as follows (in millions): Three Months Ended June 30, 2022 Gains (Losses) Unrealized Gains Foreign Employee Benefit Plans Total Beginning balance $ 5.5 $ (106.7) $ (4.8) $ (4.7) $ (110.7) Other comprehensive income (loss) before reclassifications (9.0) (33.3) (4.5) — (46.8) Amounts reclassified from accumulated other comprehensive income (loss) 13.4 (0.1) — — 13.3 Net current-period other comprehensive income (loss) 4.4 (33.4) (4.5) — (33.5) Ending balance $ 9.9 $ (140.1) $ (9.3) $ (4.7) $ (144.2) Three Months Ended June 30, 2021 Gains (Losses) Unrealized Gains Foreign Employee Benefit Plans Total Beginning balance $ 3.2 $ 19.5 $ (5.0) $ (6.3) $ 11.4 Other comprehensive income (loss) before reclassifications 0.5 (6.0) 4.9 — (0.6) Amounts reclassified from accumulated other comprehensive income (loss) (0.6) — — 0.1 (0.5) Net current-period other comprehensive income (loss) (0.1) (6.0) 4.9 0.1 (1.1) Ending balance $ 3.1 $ 13.5 $ (0.1) $ (6.2) $ 10.3 Six Months Ended June 30, 2022 Gains (Losses) on Hedge Instruments Unrealized Gains Foreign Currency Translation Gains (Losses) Employee Benefit Plans Total Beginning balance $ 4.5 $ (16.0) $ (7.9) $ (4.8) $ (24.2) Other comprehensive income (loss) before reclassifications (5.3) (124.1) (1.4) — (130.8) Amounts reclassified from accumulated other comprehensive income (loss) 10.7 — — 0.1 10.8 Net current-period other comprehensive income (loss) 5.4 (124.1) (1.4) 0.1 (120.0) Ending balance $ 9.9 $ (140.1) $ (9.3) $ (4.7) $ (144.2) Six Months Ended June 30, 2021 Gains (Losses) on Hedge Instruments Unrealized Gains Foreign Currency Translation Gains (Losses) Employee Benefit Plans Total Beginning balance $ (2.9) $ 29.5 $ 4.7 $ (6.4) $ 24.9 Other comprehensive income (loss) before reclassifications 5.1 (16.0) (4.8) — (15.7) Amounts reclassified from accumulated other comprehensive income (loss) 0.9 — — 0.2 1.1 Net current-period other comprehensive income (loss) 6.0 (16.0) (4.8) 0.2 (14.6) Ending balance $ 3.1 $ 13.5 $ (0.1) $ (6.2) $ 10.3

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	6 Months Ended
SHARE-BASED COMPENSATION	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION In April 2022, the Company’s shareholders approved an amended and restated 2010 Incentive Award Plan to provide for an increase in the number of shares of common stock reserved for issuance thereunder from 103,350,000 to 110,350,000. As of June 30, 2022, approximately 28.2 million shares were reserved for future issuance under the Company’s stock plans. A maximum of approximately 12.3 million of these shares can be awarded as restricted stock units (“RSUs”). Stock Options Information A summary of stock option activity under all stock plans for the six months ended June 30, 2022, is presented as follows (in millions, except per share amounts): Stock Options Outstanding Number Weighted-Average Balance as of December 31, 2021 11.7 $ 125.07 Options granted 0.6 $ 287.28 Options exercised (0.8) $ 80.09 Options forfeited/expired (0.1) $ 232.79 Balance as of June 30, 2022 11.4 $ 135.41 As of June 30, 2022, options to purchase an aggregate of 9.3 million shares of common stock were exercisable at a weighted average price of $108.23 per share. Restricted Stock Units Information A summary of RSUs activity under all stock plans for the six months ended June 30, 2022, is presented as follows (in millions, except per share amounts): Shares Weighted-Average Unvested balance as of December 31, 2021 4.8 $ 207.37 RSUs granted 1.7 $ 283.62 RSUs vested (1.7) $ 187.45 RSUs forfeited (0.2) $ 230.38 Unvested balance as of June 30, 2022 4.6 $ 242.33 Performance Share Units Beginning in 2022, in addition to RSUs and stock options, the Company granted performance share units (“PSUs”) to officers and other key employees subject to three-year cliff vesting and pre-established, quantitative goals. Whether any PSUs vest, and the amount that does vest, is tied to completion of service over three years and the achievement of three equally-weighted, quantitative goals that directly align with or help drive the Company’s strategy and long-term total shareholder return. The metrics are focused on relative total shareholder return (“TSR”), year-over-year procedure growth for 2023, and two-year compound annual procedure growth for 2024. TSR is considered a market condition, and the expense is determined at the grant date. This expense will not be adjusted even if the market condition is not met. The two procedure growth goals are considered performance conditions, and the expense is recorded over the vesting period based on the forecasted performance, which will be reassessed each reporting period based on the probability of achieving the two performance conditions. The number of shares earned at the end of the three-year period will vary, based on actual performance, from 0% to 125% of the target number of PSUs granted. PSUs are subject to forfeiture if employment terminates prior to the vesting date. PSUs are not considered issued or outstanding shares of the Company. The Company calculates the fair value for each component of the PSUs individually. The fair value for the component with the TSR metric was determined using Monte Carlo simulation. The fair value per share for the components with the procedure growth metrics is equal to the closing stock price on the grant date. As part of the Company’s annual grant in 2022, 0.1 million PSUs were granted at a weighted-average grant-date fair value of $299.32. Employee Stock Purchase Plan Under the Employee Stock Purchase Plan (“ESPP”), employees purchased approximately 0.2 million shares for $47.8 million and approximately 0.3 million shares for $41.4 million during the six months ended June 30, 2022, and 2021, respectively. Share-based Compensation Expense The following table summarizes share-based compensation expense for the three and six months ended June 30, 2022, and 2021 (in millions): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of sales–products $ 20.3 $ 16.6 $ 39.0 $ 31.9 Cost of sales–services 5.8 5.2 11.4 10.9 Total cost of sales 26.1 21.8 50.4 42.8 Selling, general, and administrative 62.7 55.7 123.0 108.8 Research and development 38.5 32.6 75.3 62.7 Share-based compensation expense before income taxes 127.3 110.1 248.7 214.3 Income tax benefit 20.9 22.5 48.1 43.1 Share-based compensation expense after income taxes $ 106.4 $ 87.6 $ 200.6 $ 171.2 The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s share-based compensation plans and rights to acquire stock granted under the ESPP. The weighted-average estimated fair values of stock options and the rights to acquire stock under the ESPP, as well as the weighted-average assumptions used in calculating the fair values of stock options and the rights to acquire stock under the ESPP that were granted during the three and six months ended June 30, 2022, and 2021, were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Stock Options Risk-free interest rate 2.9% 0.8% 1.7% 0.7% Expected term (in years) 3.3 4.0 3.4 4.3 Expected volatility 38% 27% 36% 33% Fair value at grant date $72.35 $63.65 $80.27 $69.96 ESPP Risk-free interest rate —% —% 0.8% 0.1% Expected term (in years) 0.0 0.0 1.2 1.2 Expected volatility —% —% 37% 35% Fair value at grant date $— $— $88.85 $74.39

INCOME TAXES

INCOME TAXES	6 Months Ended
INCOME TAXES	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXESIncome tax expense for the three months ended June 30, 2022, was $93.3 million, or 22.9% of income before taxes, compared to $3.2 million, or 0.6% of income before taxes, for the three months ended June 30, 2021. Income tax expense for the six months ended June 30, 2022, was $126.3 million, or 15.6% of income before taxes, compared to $16.8 million, or 1.7% of income before taxes, for the six months ended June 30, 2021. The effective tax rate for the three months ended June 30, 2022, differed from the U.S. federal statutory tax rate of 21% mainly due to U.S. tax on foreign earnings and state income taxes (net of federal benefit), partially offset by excess tax benefits associated with employee equity plans, the effect of income earned by certain overseas entities being taxed at rates lower than the federal statutory rate, and the federal research and development (“R&D”) credit benefit. The effective tax rates for the six months ended June 30, 2022, and for the three and six months ended June 30, 2021, differed from the U.S. federal statutory rate of 21% mainly due to excess tax benefits associated with employee equity plans, the effect of income earned by certain overseas entities being taxed at rates lower than the federal statutory rate, and the federal R&D credit benefit, partially offset by U.S. tax on foreign earnings and state income taxes (net of federal benefit). The effective tax rate for the three and six months ended June 30, 2021, included a one-time benefit of $66.4 million from re-measurement of the Company’s Swiss deferred tax assets resulting from the extension of the economic useful life of certain intangible assets. The Company files federal, state, and foreign income tax returns in many U.S. and OUS jurisdictions. Years before 2016 are closed for the significant jurisdictions. Certain of the Company’s unrecognized tax benefits could change due to activities of various tax authorities, including potential assessment of additional tax, possible settlement of audits, or through normal expiration of various statutes of limitations, which could affect the Company’s effective tax rate in the period in which they change. Due to the uncertainty related to the timing and potential outcome of audits, the Company cannot estimate the range of reasonably possible change in unrecognized tax benefits that may occur in the next 12 months. The Company is subject to the examination of its income tax returns by the Internal Revenue Service (“IRS”) and other tax authorities. The outcome of these audits cannot be predicted with certainty. The Company’s management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the Company’s provision for income taxes. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.

NET INCOME PER SHARE

NET INCOME PER SHARE	6 Months Ended
NET INCOME PER SHARE	Jun. 30, 2022
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NET INCOME PER SHARE The following table presents the computation of basic and diluted net income per share attributable to Intuitive Surgical, Inc. (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income attributable to Intuitive Surgical, Inc. $ 307.8 $ 517.2 $ 673.4 $ 943.5 Denominator: Weighted average shares outstanding used in basic calculation 358.1 355.7 358.2 355.0 Add: dilutive effect of potential common shares 5.8 9.2 7.1 9.5 Weighted average shares outstanding used in diluted calculation 363.9 364.9 365.3 364.5 Net income per share attributable to Intuitive Surgical, Inc.: Basic $ 0.86 $ 1.45 $ 1.88 $ 2.66 Diluted $ 0.85 $ 1.42 $ 1.84 $ 2.59

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) of Intuitive Surgical, Inc. and its wholly and majority-owned subsidiaries have been prepared on a consistent basis with the audited Consolidated Financial Statements for the fiscal year ended December 31, 2021, and include all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, omit certain information and footnote disclosure necessary to present the Financial Statements in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”). These Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 3, 2022. The results of operations for the first six months of 2022 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods.
Consolidation and Joint Ventures	The Financial Statements include the results and balances of the Company’s majority-owned joint venture (“Joint Venture”) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”). Chindex Medical Limited (“Chindex”), a subsidiary of Fosun Pharma, has been its distribution partner for da Vinci Surgical Systems in China. The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the consolidated stockholders’ equity. The noncontrolling interest’s share of the earnings in the Joint Venture is presented separately in the Condensed Consolidated Statements of Comprehensive Income.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Business Combinations In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company has early adopted ASU 2021-08 as of January 1, 2022, on a prospective basis. The impact of the adoption of ASU 2021-08 had an immaterial impact on the Company’s Financial Statements in the six months ended June 30, 2022. Recent Accounting Pronouncements Troubled Debt Restructurings and Vintage Disclosures In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures (“ASU 2022-02”), which eliminates the accounting guidance for troubled debt restructurings by creditors while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. Additionally, the standard requires disclosure of current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic ASC 326-20, Financial Instruments-Credit Losses-Measured at Amortized Cost . The standard will become effective for the Company beginning January 1, 2023, and should be applied prospectively. The adoption of ASU 2022-02 is not expected to have a material impact on the Company’s future Financial Statements. Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), which applies to all equity securities measured at fair value that are subject to contractual sale restrictions. This change prohibits entities from taking into account contractual restrictions on the sale of equity securities when estimating fair value and introduces required disclosures for such transactions. The standard will become effective for the Company beginning January 1, 2024, and should be applied prospectively. Early adoption is permitted. The adoption of ASU 2022-03 is not expected to have a material impact on the Company’s future Financial Statements. Significant Accounting Policies There have been no new or material changes to the significant accounting policies discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, that are of significance, or potential significance, to the Company.

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
FINANCIAL INSTRUMENTS (Tables)	Jun. 30, 2022
Investments, All Other Investments [Abstract]
Debt Securities, Available-for-sale	The following tables summarize the Company’s cash and available-for-sale marketable securities’ amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit loss, and fair value by significant investment category reported as cash and cash equivalents, short-term investments, or long-term investments as of June 30, 2022 and December 31, 2021 (in millions): Reported as: Amortized Gross Gross Allowance for Credit Loss Fair Cash and Short- Long- June 30, 2022 Cash $ 532.7 $ — $ — $ — $ 532.7 $ 532.7 $ — $ — Level 1: Money market funds 1,003.4 — — — 1,003.4 1,003.4 — — U.S. treasuries 3,330.1 — (89.6) — 3,240.5 — 1,447.1 1,793.4 Subtotal 4,333.5 — (89.6) — 4,243.9 1,003.4 1,447.1 1,793.4 Level 2: Commercial paper 310.6 — — — 310.6 — 310.6 — Corporate debt securities 2,472.2 — (69.1) (1.1) 2,402.0 — 927.5 1,474.5 U.S. government agencies 522.9 0.1 (16.7) — 506.3 — 149.9 356.4 Municipal securities 185.2 — (5.3) — 179.9 — 66.2 113.7 Subtotal 3,490.9 0.1 (91.1) (1.1) 3,398.8 — 1,454.2 1,944.6 Total assets measured at fair value $ 8,357.1 $ 0.1 $ (180.7) $ (1.1) $ 8,175.4 $ 1,536.1 $ 2,901.3 $ 3,738.0 Reported as: Amortized Gross Gross Allowance for Credit Loss Fair Cash and Short- Long- December 31, 2021 Cash $ 572.3 $ — $ — $ — $ 572.3 $ 572.3 $ — $ — Level 1: Money market funds 696.6 — — — 696.6 696.6 — — U.S. treasuries 3,429.1 6.3 (15.4) — 3,420.0 17.0 1,100.3 2,302.7 Subtotal 4,125.7 6.3 (15.4) — 4,116.6 713.6 1,100.3 2,302.7 Level 2: Commercial paper 717.7 — — — 717.7 — 717.7 — Corporate debt securities 2,485.6 2.7 (11.9) — 2,476.4 5.0 886.7 1,584.7 U.S. government agencies 526.1 0.2 (2.9) — 523.4 — 137.8 385.6 Municipal securities 213.4 0.7 (1.0) — 213.1 — 70.6 142.5 Subtotal 3,942.8 3.6 (15.8) — 3,930.6 5.0 1,812.8 2,112.8 Total assets measured at fair value $ 8,640.8 $ 9.9 $ (31.2) $ — $ 8,619.5 $ 1,290.9 $ 2,913.1 $ 4,415.5
Summary of Contractual Maturities of Cash Equivalents and Available-For-Sale Investments	The following table summarizes the contractual maturities of the Company’s cash equivalents and available-for-sale investments (excluding cash and money market funds), as of June 30, 2022 (in millions): Amortized Fair Mature in less than one year $ 2,930.9 $ 2,901.3 Mature in one to five years 3,890.1 3,738.0 Total $ 6,821.0 $ 6,639.3
Schedule of Unrealized Loss on Investments	The following tables present the breakdown of the available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category, as of June 30, 2022, and December 31, 2021 (in millions): June 30, 2022 Less than 12 months More than 12 months Total Fair Gross Fair Gross Fair Gross U.S. treasuries $ 2,882.3 $ (74.6) $ 327.0 $ (15.0) $ 3,209.3 $ (89.6) Commercial paper 3.0 — — — 3.0 — Corporate debt securities 1,917.7 (59.5) 182.3 (9.6) 2,100.0 (69.1) U.S. government agencies 479.8 (15.7) 16.5 (1.0) 496.3 (16.7) Municipal securities 130.0 (3.5) 41.5 (1.8) 171.5 (5.3) Total $ 5,412.8 $ (153.3) $ 567.3 $ (27.4) $ 5,980.1 $ (180.7) December 31, 2021 Less than 12 months More than 12 months Total Fair Gross Fair Gross Fair Gross U.S. treasuries $ 2,596.3 $ (15.4) $ — $ — $ 2,596.3 $ (15.4) Commercial paper 4.0 — — — 4.0 — Corporate debt securities 1,687.9 (11.9) — — 1,687.9 (11.9) U.S. government agencies 412.5 (2.9) — — 412.5 (2.9) Municipal securities 156.0 (1.0) — — 156.0 (1.0) Total $ 4,856.7 $ (31.2) $ — $ — $ 4,856.7 $ (31.2)
Summary of Equity Investment Activity	The following table is a summary of the activity related to equity investments (in millions): Reported as: December 31, 2021 Carrying Value Changes in Fair Value (1) Purchases/Sales June 30, 2022 Carrying Value Prepaids and other current assets Intangible and other assets, net Equity investments with readily determinable value (Level 1) $ 26.9 $ (18.3) $ — $ 8.6 $ 8.6 $ — Equity investments without readily determinable value (Level 2) $ 15.6 $ 0.2 $ 20.5 $ 36.3 $ — $ 36.3 (1) Recorded in Interest and other income (expense), net.
Derivatives Not Designated as Hedging Instruments	These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Recognized gains/(losses) in Interest and other income (expense), net $ 21.9 $ (4.0) $ 28.7 $ 7.4 Foreign exchange gains/(losses) related to balance sheet re-measurement $ (28.8) $ 5.0 $ (38.9) $ (6.0)
Gross Notional Amounts for Derivatives and Aggregate Gross Fair Value Outstanding	Total gross notional amounts (in USD) for outstanding derivatives and the aggregate gross fair value at the end of each period were as follows (in millions): Derivatives Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments June 30, December 31, June 30, December 31, Notional amounts: Forward contracts $ 204.4 $ 181.2 $ 335.1 $ 318.8 Gross fair value recorded in: Prepaids and other current assets $ 12.3 $ 5.7 $ 12.5 $ 6.9 Other accrued liabilities $ 0.8 $ 0.5 $ 1.1 $ 0.8

BALANCE SHEET DETAILS AND OTH_2

BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory	The following tables provide details of selected balance sheet line items (in millions): As of Inventory June 30, December 31, Raw materials $ 294.9 $ 214.6 Work-in-process 117.4 96.4 Finished goods 311.7 276.1 Total inventory $ 724.0 $ 587.1
Prepaids and Other Current Assets	As of Prepaids and other current assets June 30, December 31, Prepaid taxes $ 20.7 $ 4.3 Equity investments 8.6 26.9 Net investment in sales-type leases–short-term 116.5 110.3 Other prepaids and other current assets 146.8 129.6 Total prepaids and other current assets $ 292.6 $ 271.1
Other Accrued Liabilities - Short-term	As of Other accrued liabilities–short-term June 30, December 31, Taxes payable $ 40.8 $ 54.1 Current portion of deferred and contingent purchase consideration 7.2 12.0 Accrued construction-related capital expenditures 72.1 23.1 Other accrued liabilities 250.3 212.1 Total other accrued liabilities–short-term $ 370.4 $ 301.3
Other Long-term Liabilities	As of Other long-term liabilities June 30, December 31, Income taxes–long-term $ 288.2 $ 316.6 Deferred revenue–long-term 37.4 36.8 Other long-term liabilities 122.2 100.3 Total other long-term liabilities $ 447.8 $ 453.7
Supplemental Cash Flow Information	The following table provides supplemental non-cash investing and financing activities (in millions): Six Months Ended June 30, 2022 2021 Equipment transfers, including operating lease assets, from inventory to property, plant, and equipment $ 122.7 $ 139.4 Acquisition of property, plant, and equipment in accounts payable and accrued liabilities $ 95.8 $ 14.3

REVENUE AND CONTRACT ACQUISIT_2

REVENUE AND CONTRACT ACQUISITION COSTS (Tables)	6 Months Ended
REVENUE AND CONTRACT ACQUISITION COSTS (Tables)	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Disaggregated by Types and Geography	The following table presents revenue disaggregated by types and geography (in millions): Three Months Ended June 30, Six Months Ended June 30, U.S. 2022 2021 2022 2021 Instruments and accessories $ 625.1 $ 577.5 $ 1,175.7 $ 1,078.3 Systems 218.0 277.6 466.3 480.3 Services 168.0 150.7 333.9 294.7 Total U.S. revenue $ 1,011.1 $ 1,005.8 $ 1,975.9 $ 1,853.3 Outside of U.S. (“OUS”) Instruments and accessories $ 270.2 $ 218.9 $ 529.9 $ 424.0 Systems 157.1 162.0 336.9 328.0 Services 83.7 77.3 167.1 150.8 Total OUS revenue $ 511.0 $ 458.2 $ 1,033.9 $ 902.8 Total Instruments and accessories $ 895.3 $ 796.4 $ 1,705.6 $ 1,502.3 Systems 375.1 439.6 803.2 808.3 Services 251.7 228.0 501.0 445.5 Total revenue $ 1,522.1 $ 1,464.0 $ 3,009.8 $ 2,756.1
Summary of Contract Assets and Liabilities	The following information summarizes the Company’s contract assets and liabilities (in millions): As of June 30, 2022 December 31, 2021 Contract assets $ 50.6 $ 46.9 Deferred revenue $ 413.7 $ 414.0
Sales-type Lease Revenue	The following table presents revenue from Intuitive System Leasing arrangements (in millions): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales-type lease revenue $ 50.1 $ 84.0 $ 85.7 $ 101.3 Operating lease revenue* $ 93.0 $ 67.3 $ 176.2 $ 126.3 *Variable lease revenue relating to usage-based arrangements included within operating lease revenue $ 33.6 $ 21.0 $ 58.5 $ 34.5
Operating Lease Revenue	The following table presents revenue from Intuitive System Leasing arrangements (in millions): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales-type lease revenue $ 50.1 $ 84.0 $ 85.7 $ 101.3 Operating lease revenue* $ 93.0 $ 67.3 $ 176.2 $ 126.3 *Variable lease revenue relating to usage-based arrangements included within operating lease revenue $ 33.6 $ 21.0 $ 58.5 $ 34.5

LEASES (Tables)

LEASES (Tables)	6 Months Ended
LEASES (Tables)	Jun. 30, 2022
Leases [Abstract]
Schedule of Lease Receivables	Lease receivables relating to sales-type lease arrangements are presented on the Condensed Consolidated Balance Sheets as follows (in millions): As of June 30, 2022 December 31, 2021 Gross lease receivables $ 433.3 $ 404.0 Unearned income (13.5) (11.4) Subtotal 419.8 392.6 Allowance for credit loss (3.4) (3.6) Net investment in sales-type leases $ 416.4 $ 389.0 Reported as: Prepaids and other current assets $ 116.5 $ 110.3 Intangible and other assets, net 299.9 278.7 Total, net $ 416.4 $ 389.0
Schedule of Contractual Maturities of Gross Lease Receivables	Contractual maturities of gross lease receivables as of June 30, 2022, are as follows (in millions): Fiscal Year Amount Remainder of 2022 $ 63.6 2023 121.7 2024 108.3 2025 78.1 2026 46.8 2027 and thereafter 14.8 Total $ 433.3
Amortized Cost Basis by Year of Origination and Credit Quality Indicator	The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of June 30, 2022 (in millions): 2022 2021 2020 2019 2018 Prior Net Investment Credit Rating: High $ 47.6 $ 119.3 $ 61.8 $ 20.8 $ 3.4 $ 1.7 $ 254.6 Moderate 47.8 65.2 31.4 7.2 5.3 0.4 157.3 Low — 0.8 3.7 2.1 1.2 0.1 7.9 Total $ 95.4 $ 185.3 $ 96.9 $ 30.1 $ 9.9 $ 2.2 $ 419.8

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	6 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Tables)	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Summary of Changes in Goodwill	The following table summarizes the changes in the carrying amount of goodwill (in millions): Amount Balance as of December 31, 2021 $ 343.6 Acquisition activity 6.5 Translation and other (1.0) Balance as of June 30, 2022 $ 349.1
Schedule of Intangible Assets	The following table summarizes the components of gross intangible assets, accumulated amortization, and net intangible asset balances as of June 30, 2022, and December 31, 2021 (in millions): June 30, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Patents and developed technology $ 219.3 $ (180.6) $ 38.7 $ 219.3 $ (173.2) $ 46.1 Distribution rights and others 31.5 (21.5) 10.0 26.3 (19.4) 6.9 Customer relationships 33.5 (16.0) 17.5 31.8 (14.3) 17.5 Total intangible assets $ 284.3 $ (218.1) $ 66.2 $ 277.4 $ (206.9) $ 70.5
Schedule Of Estimated Future Amortization Expense Of Intangible Assets	The estimated future amortization expense related to intangible assets as of June 30, 2022, is as follows (in millions): Fiscal Year Amount Remainder of 2022 $ 16.0 2023 19.6 2024 15.6 2025 10.3 2026 3.3 2027 and thereafter 1.4 Total $ 66.2

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Jun. 30, 2022
Equity [Abstract]
Schedule of Stockholders Equity	The following tables present the changes in stockholders’ equity (in millions): Three Months Ended June 30, 2022 Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Intuitive Surgical, Inc. Stockholders’ Equity Noncontrolling Interest in Joint Venture Total Stockholders’ Equity Shares Amount Beginning balance 358.9 $ 0.4 $ 7,354.6 $ 4,858.0 $ (110.7) $ 12,102.3 $ 54.6 $ 12,156.9 Issuance of common stock through employee stock plans 0.4 — 26.6 — — 26.6 — 26.6 Shares withheld related to net share settlement of equity awards — — (0.6) (6.2) — (6.8) — (6.8) Share-based compensation expense related to employee stock plans — — 126.7 — — 126.7 — 126.7 Repurchase and retirement of common stock (2.2) — (23.3) (476.8) — (500.1) — (500.1) Net income attributable to Intuitive Surgical, Inc. — — — 307.8 — 307.8 — 307.8 Other comprehensive income (loss) — — — — (33.5) (33.5) (1.0) (34.5) Net income attributable to noncontrolling interest in joint venture — — — — — — 5.8 5.8 Ending balance 357.1 $ 0.4 $ 7,484.0 $ 4,682.8 $ (144.2) $ 12,023.0 $ 59.4 $ 12,082.4 Three Months Ended June 30, 2021 Common Stock Additional Retained Accumulated Total Intuitive Surgical, Inc. Stockholders’ Equity Noncontrolling Interest in Joint Venture Total Stockholders’ Equity Shares Amount Beginning balance 355.2 $ 0.4 $ 6,627.0 $ 3,514.7 $ 11.4 $ 10,153.5 $ 36.7 $ 10,190.2 Issuance of common stock through employee stock plans 1.0 — 69.7 — — 69.7 — 69.7 Shares withheld related to net share settlement of equity awards — — (0.7) (9.2) — (9.9) — (9.9) Share-based compensation expense related to employee stock plans — — 108.1 — — 108.1 — 108.1 Net income attributable to Intuitive Surgical, Inc. — — — 517.2 — 517.2 — 517.2 Other comprehensive income (loss) — — — — (1.1) (1.1) (0.5) (1.6) Net income attributable to noncontrolling interest in joint venture — — — — — — 5.8 5.8 Ending balance 356.2 $ 0.4 $ 6,804.1 $ 4,022.7 $ 10.3 $ 10,837.5 $ 42.0 $ 10,879.5 Six Months Ended June 30, 2022 Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Intuitive Surgical, Inc. Stockholders’ Equity Noncontrolling Interest in Joint Venture Total Stockholders’ Equity Shares Amount Beginning balance 357.7 $ 0.4 $ 7,164.0 $ 4,760.9 $ (24.2) $ 11,901.1 $ 50.4 $ 11,951.5 Issuance of common stock through employee stock plans 2.6 — 106.6 — — 106.6 — 106.6 Shares withheld related to net share settlement of equity awards (0.6) — (6.7) (172.3) — (179.0) — (179.0) Share-based compensation expense related to employee stock plans — — 247.5 — — 247.5 — 247.5 Repurchase and retirement of common stock (2.6) — (27.4) (579.2) — (606.6) — (606.6) Net income attributable to Intuitive Surgical, Inc. — — — 673.4 — 673.4 — 673.4 Other comprehensive income (loss) — — — — (120.0) (120.0) (0.6) (120.6) Net income attributable to noncontrolling interest in joint venture — — — — — — 9.6 9.6 Ending balance 357.1 $ 0.4 $ 7,484.0 $ 4,682.8 $ (144.2) $ 12,023.0 $ 59.4 $ 12,082.4 Six Months Ended June 30, 2021 Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Intuitive Surgical, Inc. Stockholders’ Equity Noncontrolling Interest in Joint Venture Total Stockholders’ Equity Shares Amount Beginning balance 353.1 $ 0.4 $ 6,444.9 $ 3,261.3 $ 24.9 $ 9,731.5 $ 27.6 $ 9,759.1 Issuance of common stock through employee stock plans 3.8 — 153.7 — — 153.7 — 153.7 Shares withheld related to net share settlement of equity awards (0.7) — (5.8) (182.1) — (187.9) — (187.9) Share-based compensation expense related to employee stock plans — — 211.3 — — 211.3 — 211.3 Net income attributable to Intuitive Surgical, Inc. — — — 943.5 — 943.5 — 943.5 Other comprehensive income (loss) — — — — (14.6) (14.6) (0.3) (14.9) Net income attributable to noncontrolling interest in joint venture — — — — — — 14.7 14.7 Ending balance 356.2 $ 0.4 $ 6,804.1 $ 4,022.7 $ 10.3 $ 10,837.5 $ 42.0 $ 10,879.5
Schedule of Share Repurchase Activities	The following table provides share repurchase activities (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Shares repurchased 2.2 — 2.6 — Average price per share $ 224.4 $ — $ 231.0 $ — Value of shares repurchased $ 500.1 $ — $ 606.6 $ —
Components of Accumulated Other Comprehensive Income, Net of Tax	The components of accumulated other comprehensive income (loss), net of tax, attributable to Intuitive Surgical, Inc. are as follows (in millions): Three Months Ended June 30, 2022 Gains (Losses) Unrealized Gains Foreign Employee Benefit Plans Total Beginning balance $ 5.5 $ (106.7) $ (4.8) $ (4.7) $ (110.7) Other comprehensive income (loss) before reclassifications (9.0) (33.3) (4.5) — (46.8) Amounts reclassified from accumulated other comprehensive income (loss) 13.4 (0.1) — — 13.3 Net current-period other comprehensive income (loss) 4.4 (33.4) (4.5) — (33.5) Ending balance $ 9.9 $ (140.1) $ (9.3) $ (4.7) $ (144.2) Three Months Ended June 30, 2021 Gains (Losses) Unrealized Gains Foreign Employee Benefit Plans Total Beginning balance $ 3.2 $ 19.5 $ (5.0) $ (6.3) $ 11.4 Other comprehensive income (loss) before reclassifications 0.5 (6.0) 4.9 — (0.6) Amounts reclassified from accumulated other comprehensive income (loss) (0.6) — — 0.1 (0.5) Net current-period other comprehensive income (loss) (0.1) (6.0) 4.9 0.1 (1.1) Ending balance $ 3.1 $ 13.5 $ (0.1) $ (6.2) $ 10.3 Six Months Ended June 30, 2022 Gains (Losses) on Hedge Instruments Unrealized Gains Foreign Currency Translation Gains (Losses) Employee Benefit Plans Total Beginning balance $ 4.5 $ (16.0) $ (7.9) $ (4.8) $ (24.2) Other comprehensive income (loss) before reclassifications (5.3) (124.1) (1.4) — (130.8) Amounts reclassified from accumulated other comprehensive income (loss) 10.7 — — 0.1 10.8 Net current-period other comprehensive income (loss) 5.4 (124.1) (1.4) 0.1 (120.0) Ending balance $ 9.9 $ (140.1) $ (9.3) $ (4.7) $ (144.2) Six Months Ended June 30, 2021 Gains (Losses) on Hedge Instruments Unrealized Gains Foreign Currency Translation Gains (Losses) Employee Benefit Plans Total Beginning balance $ (2.9) $ 29.5 $ 4.7 $ (6.4) $ 24.9 Other comprehensive income (loss) before reclassifications 5.1 (16.0) (4.8) — (15.7) Amounts reclassified from accumulated other comprehensive income (loss) 0.9 — — 0.2 1.1 Net current-period other comprehensive income (loss) 6.0 (16.0) (4.8) 0.2 (14.6) Ending balance $ 3.1 $ 13.5 $ (0.1) $ (6.2) $ 10.3

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
SHARE-BASED COMPENSATION (Tables)	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity Under All Stock Plans	A summary of stock option activity under all stock plans for the six months ended June 30, 2022, is presented as follows (in millions, except per share amounts): Stock Options Outstanding Number Weighted-Average Balance as of December 31, 2021 11.7 $ 125.07 Options granted 0.6 $ 287.28 Options exercised (0.8) $ 80.09 Options forfeited/expired (0.1) $ 232.79 Balance as of June 30, 2022 11.4 $ 135.41
Summary of RSU Activity	A summary of RSUs activity under all stock plans for the six months ended June 30, 2022, is presented as follows (in millions, except per share amounts): Shares Weighted-Average Unvested balance as of December 31, 2021 4.8 $ 207.37 RSUs granted 1.7 $ 283.62 RSUs vested (1.7) $ 187.45 RSUs forfeited (0.2) $ 230.38 Unvested balance as of June 30, 2022 4.6 $ 242.33
Summary of Share-Based Compensation Expense	The following table summarizes share-based compensation expense for the three and six months ended June 30, 2022, and 2021 (in millions): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of sales–products $ 20.3 $ 16.6 $ 39.0 $ 31.9 Cost of sales–services 5.8 5.2 11.4 10.9 Total cost of sales 26.1 21.8 50.4 42.8 Selling, general, and administrative 62.7 55.7 123.0 108.8 Research and development 38.5 32.6 75.3 62.7 Share-based compensation expense before income taxes 127.3 110.1 248.7 214.3 Income tax benefit 20.9 22.5 48.1 43.1 Share-based compensation expense after income taxes $ 106.4 $ 87.6 $ 200.6 $ 171.2
Schedule of Estimated Fair Value of the Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions	The weighted-average estimated fair values of stock options and the rights to acquire stock under the ESPP, as well as the weighted-average assumptions used in calculating the fair values of stock options and the rights to acquire stock under the ESPP that were granted during the three and six months ended June 30, 2022, and 2021, were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Stock Options Risk-free interest rate 2.9% 0.8% 1.7% 0.7% Expected term (in years) 3.3 4.0 3.4 4.3 Expected volatility 38% 27% 36% 33% Fair value at grant date $72.35 $63.65 $80.27 $69.96 ESPP Risk-free interest rate —% —% 0.8% 0.1% Expected term (in years) 0.0 0.0 1.2 1.2 Expected volatility —% —% 37% 35% Fair value at grant date $— $— $88.85 $74.39

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	6 Months Ended
NET INCOME PER SHARE (Tables)	Jun. 30, 2022
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income Per Share	The following table presents the computation of basic and diluted net income per share attributable to Intuitive Surgical, Inc. (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income attributable to Intuitive Surgical, Inc. $ 307.8 $ 517.2 $ 673.4 $ 943.5 Denominator: Weighted average shares outstanding used in basic calculation 358.1 355.7 358.2 355.0 Add: dilutive effect of potential common shares 5.8 9.2 7.1 9.5 Weighted average shares outstanding used in diluted calculation 363.9 364.9 365.3 364.5 Net income per share attributable to Intuitive Surgical, Inc.: Basic $ 0.86 $ 1.45 $ 1.88 $ 2.66 Diluted $ 0.85 $ 1.42 $ 1.84 $ 2.59

FINANCIAL INSTRUMENTS - Summary

FINANCIAL INSTRUMENTS - Summary of Cash and Available-For-Sale Securities (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	$ 1,536.1	$ 1,290.9
Total	6,821
Gross Unrealized Gains	0.1	9.9
Gross Unrealized Losses	(180.7)	(31.2)
Allowance for Credit Loss	(1.1)	0
Fair Value	6,639.3
Short- term Investments	2,901.3	2,913.1
Long- term Investments	3,738	4,415.5
Total assets measured at fair value, amortized cost	8,357.1	8,640.8
Total assets measured at fair value, fair value	8,175.4	8,619.5
Cash
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	532.7	572.3
Fair Value	532.7	572.3
Level 1
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	1,003.4	713.6
Total	4,333.5	4,125.7
Gross Unrealized Gains	0	6.3
Gross Unrealized Losses	(89.6)	(15.4)
Allowance for Credit Loss	0	0
Fair Value	4,243.9	4,116.6
Short- term Investments	1,447.1	1,100.3
Long- term Investments	1,793.4	2,302.7
Level 1 \| Money market funds
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	1,003.4	696.6
Fair Value	1,003.4	696.6
Short- term Investments	0	0
Long- term Investments	0	0
Level 1 \| U.S. treasuries
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	0	17
Total	3,330.1	3,429.1
Gross Unrealized Gains	0	6.3
Gross Unrealized Losses	(89.6)	(15.4)
Allowance for Credit Loss	0	0
Fair Value	3,240.5	3,420
Short- term Investments	1,447.1	1,100.3
Long- term Investments	1,793.4	2,302.7
Level 2
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	0	5
Total	3,490.9	3,942.8
Gross Unrealized Gains	0.1	3.6
Gross Unrealized Losses	(91.1)	(15.8)
Allowance for Credit Loss	(1.1)	0
Fair Value	3,398.8	3,930.6
Short- term Investments	1,454.2	1,812.8
Long- term Investments	1,944.6	2,112.8
Level 2 \| Commercial paper
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	0	0
Total	310.6	717.7
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Allowance for Credit Loss	0	0
Fair Value	310.6	717.7
Short- term Investments	310.6	717.7
Long- term Investments	0	0
Level 2 \| Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	0	5
Total	2,472.2	2,485.6
Gross Unrealized Gains	0	2.7
Gross Unrealized Losses	(69.1)	(11.9)
Allowance for Credit Loss	(1.1)	0
Fair Value	2,402	2,476.4
Short- term Investments	927.5	886.7
Long- term Investments	1,474.5	1,584.7
Level 2 \| U.S. government agencies
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	0	0
Total	522.9	526.1
Gross Unrealized Gains	0.1	0.2
Gross Unrealized Losses	(16.7)	(2.9)
Allowance for Credit Loss	0	0
Fair Value	506.3	523.4
Short- term Investments	149.9	137.8
Long- term Investments	356.4	385.6
Level 2 \| Municipal securities
Debt Securities, Available-for-sale [Line Items]
Cash and Cash Equivalents	0	0
Total	185.2	213.4
Gross Unrealized Gains	0	0.7
Gross Unrealized Losses	(5.3)	(1)
Allowance for Credit Loss	0	0
Fair Value	179.9	213.1
Short- term Investments	66.2	70.6
Long- term Investments	$ 113.7	$ 142.5

FINANCIAL INSTRUMENTS - Summa_2

FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-For-Sale Investments (Details) $ in Millions	Jun. 30, 2022 USD ($)
Amortized Cost
Mature in less than one year	$ 2,930.9
Mature in one to five years	3,890.1
Total	6,821
Fair Value
Mature in less than one year	2,901.3
Mature in one to five years	3,738
Total	$ 6,639.3

FINANCIAL INSTRUMENTS - Availab

FINANCIAL INSTRUMENTS - Available-for-Sale Debt Securities in a Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Unrealized losses less than 12 months, fair value	$ 5,412.8	$ 4,856.7
Unrealized losses less than 12 months, gross unrealized losses	(153.3)	(31.2)
Unrealized losses more than 12 months, fair value	567.3	0
Unrealized losses more than 12 months, gross unrealized losses	(27.4)	0
Total unrealized losses, fair value	5,980.1	4,856.7
Total unrealized losses, gross unrealized losses	(180.7)	(31.2)
U.S. treasuries
Debt Securities, Available-for-sale [Line Items]
Unrealized losses less than 12 months, fair value	2,882.3	2,596.3
Unrealized losses less than 12 months, gross unrealized losses	(74.6)	(15.4)
Unrealized losses more than 12 months, fair value	327	0
Unrealized losses more than 12 months, gross unrealized losses	(15)	0
Total unrealized losses, fair value	3,209.3	2,596.3
Total unrealized losses, gross unrealized losses	(89.6)	(15.4)
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Unrealized losses less than 12 months, fair value	3	4
Unrealized losses less than 12 months, gross unrealized losses	0	0
Unrealized losses more than 12 months, fair value	0	0
Unrealized losses more than 12 months, gross unrealized losses	0	0
Total unrealized losses, fair value	3	4
Total unrealized losses, gross unrealized losses	0	0
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Unrealized losses less than 12 months, fair value	1,917.7	1,687.9
Unrealized losses less than 12 months, gross unrealized losses	(59.5)	(11.9)
Unrealized losses more than 12 months, fair value	182.3	0
Unrealized losses more than 12 months, gross unrealized losses	(9.6)	0
Total unrealized losses, fair value	2,100	1,687.9
Total unrealized losses, gross unrealized losses	(69.1)	(11.9)
U.S. government agencies
Debt Securities, Available-for-sale [Line Items]
Unrealized losses less than 12 months, fair value	479.8	412.5
Unrealized losses less than 12 months, gross unrealized losses	(15.7)	(2.9)
Unrealized losses more than 12 months, fair value	16.5	0
Unrealized losses more than 12 months, gross unrealized losses	(1)	0
Total unrealized losses, fair value	496.3	412.5
Total unrealized losses, gross unrealized losses	(16.7)	(2.9)
Municipal securities
Debt Securities, Available-for-sale [Line Items]
Unrealized losses less than 12 months, fair value	130	156
Unrealized losses less than 12 months, gross unrealized losses	(3.5)	(1)
Unrealized losses more than 12 months, fair value	41.5	0
Unrealized losses more than 12 months, gross unrealized losses	(1.8)	0
Total unrealized losses, fair value	171.5	156
Total unrealized losses, gross unrealized losses	$ (5.3)	$ (1)

FINANCIAL INSTRUMENTS - Summa_3

FINANCIAL INSTRUMENTS - Summary of Equity Investment Activity (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Fair Value, Level 1 [Abstract]
Beginning balance, carrying value		$ 26.9
Ending balance, carrying value	$ 8.6	8.6
Level 1
Fair Value, Level 1 [Abstract]
Beginning balance, carrying value		26.9
Purchases/Sales		0
Ending balance, carrying value	8.6	8.6
Level 1 \| Broncus Holding Corporation
Fair Value, Level 1 [Abstract]
Changes in fair value	(1.1)	(18.3)
Level 2
Fair Value, Level 2 [Abstract]
Beginning balance, carrying value		15.6
Changes in Fair Value		0.2
Purchases/Sales		20.5
Ending balance, carrying value	36.3	36.3
Prepaids and other current assets \| Level 1
Fair Value, Level 1 [Abstract]
Ending balance, carrying value	8.6	8.6
Prepaids and other current assets \| Level 2
Fair Value, Level 2 [Abstract]
Ending balance, carrying value	0	0
Intangible and other assets, net \| Level 1
Fair Value, Level 1 [Abstract]
Ending balance, carrying value	0	0
Intangible and other assets, net \| Level 2
Fair Value, Level 2 [Abstract]
Ending balance, carrying value	$ 36.3	$ 36.3

FINANCIAL INSTRUMENTS - Narrati

FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021
Collar Contract \| Derivatives Not Designated as Hedging Instruments \| Other income
Debt and Equity Securities, FV-NI [Line Items]
Recognized gains/(losses) in Interest and other income (expense), net			$ (7.5)
Broncus Holding Corporation \| Level 1
Debt and Equity Securities, FV-NI [Line Items]
Changes in fair value	$ (1.1)	$ (18.3)

FINANCIAL INSTRUMENTS - Derivat

FINANCIAL INSTRUMENTS - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange gains/(losses) related to balance sheet re-measurement	$ (28.8)	$ 5	$ (38.9)	$ (6)
Forward contracts \| Other income \| Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized gains/(losses) in Interest and other income (expense), net	$ 21.9	$ (4)	$ 28.7	$ 7.4

FINANCIAL INSTRUMENTS - Gross N

FINANCIAL INSTRUMENTS - Gross Notional Amounts for Outstanding Derivatives (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Derivatives Designated as Hedging Instruments \| Prepaids and other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	$ 12.3	$ 5.7
Derivatives Designated as Hedging Instruments \| Other accrued liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	0.8	0.5
Derivatives Not Designated as Hedging Instruments \| Prepaids and other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	12.5	6.9
Derivatives Not Designated as Hedging Instruments \| Other accrued liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	1.1	0.8
Forward contracts \| Derivatives Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	204.4	181.2
Forward contracts \| Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	$ 335.1	$ 318.8

BALANCE SHEET DETAILS AND OTH_3

BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION - Inventory (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 294.9	$ 214.6
Work-in-process	117.4	96.4
Finished goods	311.7	276.1
Total inventory	$ 724	$ 587.1

BALANCE SHEET DETAILS AND OTH_4

BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION - Prepaids and Other Current Assets (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid taxes	$ 20.7	$ 4.3
Equity investments	8.6	26.9
Net investment in sales-type leases–short-term	116.5	110.3
Other prepaids and other current assets	146.8	129.6
Total prepaids and other current assets	$ 292.6	$ 271.1

BALANCE SHEET DETAILS AND OTH_5

BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION - Other Accrued Liabilities - Short-term (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Taxes payable	$ 40.8	$ 54.1
Current portion of deferred and contingent purchase consideration	7.2	12
Accrued construction-related capital expenditures	72.1	23.1
Other accrued liabilities	250.3	212.1
Total other accrued liabilities–short-term	$ 370.4	$ 301.3

BALANCE SHEET DETAILS AND OTH_6

BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION - Other Long-term Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Income taxes–long-term	$ 288.2	$ 316.6
Deferred revenue–long-term	37.4	36.8
Other long-term liabilities	122.2	100.3
Total other long-term liabilities	$ 447.8	$ 453.7

BALANCE SHEET DETAILS AND OTH_7

BALANCE SHEET DETAILS AND OTHER FINANCIAL INFORMATION - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Equipment transfers, including operating lease assets, from inventory to property, plant, and equipment	$ 122.7	$ 139.4
Acquisition of property, plant, and equipment in accounts payable and accrued liabilities	$ 95.8	$ 14.3

REVENUE AND CONTRACT ACQUISIT_3

REVENUE AND CONTRACT ACQUISITION COSTS - Revenue Disaggregated by Types and Geography (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,522.1	$ 1,464	$ 3,009.8	$ 2,756.1
Instruments and accessories
Disaggregation of Revenue [Line Items]
Total revenue	895.3	796.4	1,705.6	1,502.3
Systems
Disaggregation of Revenue [Line Items]
Total revenue	375.1	439.6	803.2	808.3
Services
Disaggregation of Revenue [Line Items]
Total revenue	251.7	228	501	445.5
U.S.
Disaggregation of Revenue [Line Items]
Total revenue	1,011.1	1,005.8	1,975.9	1,853.3
U.S. \| Instruments and accessories
Disaggregation of Revenue [Line Items]
Total revenue	625.1	577.5	1,175.7	1,078.3
U.S. \| Systems
Disaggregation of Revenue [Line Items]
Total revenue	218	277.6	466.3	480.3
U.S. \| Services
Disaggregation of Revenue [Line Items]
Total revenue	168	150.7	333.9	294.7
Outside of U.S. (“OUS”)
Disaggregation of Revenue [Line Items]
Total revenue	511	458.2	1,033.9	902.8
Outside of U.S. (“OUS”) \| Instruments and accessories
Disaggregation of Revenue [Line Items]
Total revenue	270.2	218.9	529.9	424
Outside of U.S. (“OUS”) \| Systems
Disaggregation of Revenue [Line Items]
Total revenue	157.1	162	336.9	328
Outside of U.S. (“OUS”) \| Services
Disaggregation of Revenue [Line Items]
Total revenue	$ 83.7	$ 77.3	$ 167.1	$ 150.8

REVENUE AND CONTRACT ACQUISIT_4

REVENUE AND CONTRACT ACQUISITION COSTS - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue recognized	$ 125	$ 99	$ 318	$ 250
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Price allocated to remaining performance obligations	$ 1,830		$ 1,830
Remaining performance obligations	5 years		5 years

REVENUE AND CONTRACT ACQUISIT_5

REVENUE AND CONTRACT ACQUISITION COSTS - Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Contract assets	$ 50.6	$ 46.9
Deferred revenue	$ 413.7	$ 414

REVENUE AND CONTRACT ACQUISIT_6

REVENUE AND CONTRACT ACQUISITION COSTS - Sales-type and Operating Lease Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Deferred Revenue Arrangement [Line Items]
Sales-type lease revenue	$ 50.1	$ 84	$ 85.7	$ 101.3
Operating lease revenue	93	67.3	176.2	126.3
Variable Lease Revenue, Usage-Based Arrangements
Deferred Revenue Arrangement [Line Items]
Operating lease revenue	$ 33.6	$ 21	$ 58.5	$ 34.5

LEASES - Lease Receivables (Det

LEASES - Lease Receivables (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Capital Leased Assets [Line Items]
Gross lease receivables	$ 433.3	$ 404
Unearned income	(13.5)	(11.4)
Subtotal	419.8	392.6
Allowance for credit loss	(3.4)	(3.6)
Sales-type lease, lease receivable	416.4	389
Prepaids and other current assets
Capital Leased Assets [Line Items]
Sales-type lease, lease receivable	116.5	110.3
Intangible and other assets, net
Capital Leased Assets [Line Items]
Sales-type lease, lease receivable	$ 299.9	$ 278.7

LEASES - Schedule of Contractua

LEASES - Schedule of Contractual Maturities of Gross Lease Receivables (Details) $ in Millions	Jun. 30, 2022 USD ($)
Leases [Abstract]
Remainder of 2022	$ 63.6
2023	121.7
2024	108.3
2025	78.1
2026	46.8
2027 and thereafter	14.8
Total	$ 433.3

LEASES - Additional Information

LEASES - Additional Information (Details)	Jun. 30, 2022
Minimum
Lessee, Lease, Description [Line Items]
Sales-type leases terms	24 months
Maximum
Lessee, Lease, Description [Line Items]
Sales-type leases terms	84 months

LEASES - Credit Quality Indicat

LEASES - Credit Quality Indicator (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]
2022	$ 95.4
2021	185.3
2020	96.9
2019	30.1
2018	9.9
Prior	2.2
Subtotal	419.8	$ 392.6
High
Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]
2022	47.6
2021	119.3
2020	61.8
2019	20.8
2018	3.4
Prior	1.7
Subtotal	254.6
Moderate
Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]
2022	47.8
2021	65.2
2020	31.4
2019	7.2
2018	5.3
Prior	0.4
Subtotal	157.3
Low
Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]
2022	0
2021	0.8
2020	3.7
2019	2.1
2018	1.2
Prior	0.1
Subtotal	$ 7.9

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Schedule of Summary of Changes in Goodwill (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 343.6
Acquisition activity	6.5
Translation and other	(1)
Goodwill, ending balance	$ 349.1

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 284.3	$ 277.4
Accumulated Amortization	(218.1)	(206.9)
Net Carrying Amount	66.2	70.5
Patents and developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	219.3	219.3
Accumulated Amortization	(180.6)	(173.2)
Net Carrying Amount	38.7	46.1
Distribution rights and others
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	31.5	26.3
Accumulated Amortization	(21.5)	(19.4)
Net Carrying Amount	10	6.9
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	33.5	31.8
Accumulated Amortization	(16)	(14.3)
Net Carrying Amount	$ 17.5	$ 17.5

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 6.2	$ 7.6	$ 12.3	$ 14.5

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2022	$ 16
2023	19.6
2024	15.6
2025	10.3
2026	3.3
2027 and thereafter	1.4
Net Carrying Amount	$ 66.2	$ 70.5

STOCKHOLDERS' EQUITY - Schedule

STOCKHOLDERS' EQUITY - Schedule of Stockholders Equity (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)			357.7
Beginning balance	$ 12,156.9	$ 10,190.2	$ 11,951.5	$ 9,759.1
Issuance of common stock through employee stock plans	26.6	69.7	106.6	153.7
Shares withheld related to net share settlement of equity awards	(6.8)	(9.9)	(179)	(187.9)
Share-based compensation expense related to employee stock plans	126.7	108.1	247.5	211.3
Repurchase and retirement of common stock	(500.1)		(606.6)
Net income attributable to Intuitive Surgical, Inc.	307.8	517.2	673.4	943.5
Other comprehensive income (loss)	(34.5)	(1.6)	(120.6)	(14.9)
Net income attributable to noncontrolling interest in joint venture	$ 5.8	5.8	$ 9.6	14.7
Ending balance (in shares)	357.1		357.1
Ending balance	$ 12,082.4	10,879.5	$ 12,082.4	10,879.5
Total Intuitive Surgical, Inc. Stockholders’ Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	12,102.3	10,153.5	11,901.1	9,731.5
Issuance of common stock through employee stock plans	26.6	69.7	106.6	153.7
Shares withheld related to net share settlement of equity awards	(6.8)	(9.9)	(179)	(187.9)
Share-based compensation expense related to employee stock plans	126.7	108.1	247.5	211.3
Repurchase and retirement of common stock	(500.1)		(606.6)
Net income attributable to Intuitive Surgical, Inc.	307.8	517.2	673.4	943.5
Other comprehensive income (loss)	(33.5)	(1.1)	(120)	(14.6)
Ending balance	$ 12,023	$ 10,837.5	$ 12,023	$ 10,837.5
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	358.9	355.2	357.7	353.1
Beginning balance	$ 0.4	$ 0.4	$ 0.4	$ 0.4
Issuance of common stock through employee stock plans (in shares)	0.4	1	2.6	3.8
Shares withheld related to net share settlement of equity awards (in shares)	0	0	(0.6)	(0.7)
Repurchase and retirement of common stock (in shares)	(2.2)		(2.6)
Ending balance (in shares)	357.1	356.2	357.1	356.2
Ending balance	$ 0.4	$ 0.4	$ 0.4	$ 0.4
Additional Paid-In Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	7,354.6	6,627	7,164	6,444.9
Issuance of common stock through employee stock plans	26.6	69.7	106.6	153.7
Shares withheld related to net share settlement of equity awards	(0.6)	(0.7)	(6.7)	(5.8)
Share-based compensation expense related to employee stock plans	126.7	108.1	247.5	211.3
Repurchase and retirement of common stock	(23.3)		(27.4)
Ending balance	7,484	6,804.1	7,484	6,804.1
Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	4,858	3,514.7	4,760.9	3,261.3
Shares withheld related to net share settlement of equity awards	(6.2)	(9.2)	(172.3)	(182.1)
Repurchase and retirement of common stock	(476.8)		(579.2)
Net income attributable to Intuitive Surgical, Inc.	307.8	517.2	673.4	943.5
Ending balance	4,682.8	4,022.7	4,682.8	4,022.7
Accumulated Other Comprehensive Income (Loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(110.7)	11.4	(24.2)	24.9
Other comprehensive income (loss)	(33.5)	(1.1)	(120)	(14.6)
Ending balance	(144.2)	10.3	(144.2)	10.3
Noncontrolling Interest in Joint Venture
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	54.6	36.7	50.4	27.6
Other comprehensive income (loss)	(1)	(0.5)	(0.6)	(0.3)
Net income attributable to noncontrolling interest in joint venture	5.8	5.8	9.6	14.7
Ending balance	$ 59.4	$ 42	$ 59.4	$ 42

STOCKHOLDERS' EQUITY - Stock Re

STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) - Repurchase Program - Common Stock - USD ($)	Jul. 20, 2022	Jun. 30, 2022	Jan. 31, 2019
Equity, Class of Treasury Stock [Line Items]
Amount of share repurchases authorized		$ 7,500,000,000
Stock repurchase program, increased to authorized amount			$ 2,000,000,000
Remaining amount of share repurchases authorized		$ 1,000,000,000
Subsequent event
Equity, Class of Treasury Stock [Line Items]
Remaining amount of share repurchases authorized	$ 3,500,000,000

STOCKHOLDERS' EQUITY - Schedu_2

STOCKHOLDERS' EQUITY - Schedule of Share Repurchase Activities (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Equity, Class of Treasury Stock [Line Items]
Value of shares repurchased	$ 500.1		$ 606.6
Common Stock
Equity, Class of Treasury Stock [Line Items]
Shares repurchased (in shares)	2.2		2.6
Common Stock \| Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Shares repurchased (in shares)	2.2	0	2.6	0
Average price per share (in dollars per share)	$ 224.4	$ 0	$ 231	$ 0
Value of shares repurchased	$ 500.1	$ 0	$ 606.6	$ 0

STOCKHOLDERS' EQUITY - Componen

STOCKHOLDERS' EQUITY - Components of Accumulated Other Comprehensive Income, Net of Tax (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ (110.7)	$ 11.4	$ (24.2)	$ 24.9
Other comprehensive income (loss) before reclassifications	(46.8)	(0.6)	(130.8)	(15.7)
Amounts reclassified from accumulated other comprehensive income (loss)	13.3	(0.5)	10.8	1.1
Net current-period other comprehensive income (loss)	(33.5)	(1.1)	(120)	(14.6)
Ending balance	(144.2)	10.3	(144.2)	10.3
Gains (Losses) on Hedge Instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	5.5	3.2	4.5	(2.9)
Other comprehensive income (loss) before reclassifications	(9)	0.5	(5.3)	5.1
Amounts reclassified from accumulated other comprehensive income (loss)	13.4	(0.6)	10.7	0.9
Net current-period other comprehensive income (loss)	4.4	(0.1)	5.4	6
Ending balance	9.9	3.1	9.9	3.1
Unrealized Gains (Losses) on Available-for-Sale Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(106.7)	19.5	(16)	29.5
Other comprehensive income (loss) before reclassifications	(33.3)	(6)	(124.1)	(16)
Amounts reclassified from accumulated other comprehensive income (loss)	(0.1)	0	0	0
Net current-period other comprehensive income (loss)	(33.4)	(6)	(124.1)	(16)
Ending balance	(140.1)	13.5	(140.1)	13.5
Foreign Currency Translation Gains (Losses)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(4.8)	(5)	(7.9)	4.7
Other comprehensive income (loss) before reclassifications	(4.5)	4.9	(1.4)	(4.8)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0	0	0
Net current-period other comprehensive income (loss)	(4.5)	4.9	(1.4)	(4.8)
Ending balance	(9.3)	(0.1)	(9.3)	(0.1)
Employee Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(4.7)	(6.3)	(4.8)	(6.4)
Other comprehensive income (loss) before reclassifications	0	0	0	0
Amounts reclassified from accumulated other comprehensive income (loss)	0	0.1	0.1	0.2
Net current-period other comprehensive income (loss)	0	0.1	0.1	0.2
Ending balance	$ (4.7)	$ (6.2)	$ (4.7)	$ (6.2)

SHARE-BASED COMPENSATION - Addi

SHARE-BASED COMPENSATION - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Apr. 01, 2022	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable, number of shares	9,300,000
Options exercisable, weighted-average exercise price (usd per share)	$ 108.23
Employee Stock Purchase Plan, number of shares purchased by employees	200,000	300,000
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	1,700,000
Granted (usd per share)	$ 283.62
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Stock Purchase Plan, value of shares purchased by employees	$ 47.8	$ 41.4
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	100,000
Granted (usd per share)	$ 299.32
2010 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance			110,350,000	103,350,000
Number of shares reserved for future issuance	28,200,000
2010 Incentive Award Plan \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for future issuance	12,300,000

SHARE-BASED COMPENSATION - Summ

SHARE-BASED COMPENSATION - Summary of Stock Option Activity Under All Stock Plans (Details) shares in Millions	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Number Outstanding
Beginning balance (in shares) \| shares	11.7
Options granted (in shares) \| shares	0.6
Options exercised (in shares) \| shares	(0.8)
Options forfeited/expired (in shares) \| shares	(0.1)
Ending balance (in shares) \| shares	11.4
Weighted-Average Exercise Price Per Share
Beginning balance, Weighted Average Exercise Price Per Share \| $ / shares	$ 125.07
Options granted, Weighted Average Exercise Price Per Share \| $ / shares	287.28
Options exercised, Weighted Average Exercise Price Per Share \| $ / shares	80.09
Options forfeited/expired, Weighted Average Exercise Price Per Share \| $ / shares	232.79
Ending balance, Weighted Average Exercise Price Per Share \| $ / shares	$ 135.41

SHARE-BASED COMPENSATION - Su_2

SHARE-BASED COMPENSATION - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) shares in Millions	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Shares
Unvested beginning balance (in shares) \| shares	4.8
Granted (in shares) \| shares	1.7
Vested (in shares) \| shares	(1.7)
Forfeited (in shares) \| shares	(0.2)
Unvested ending balance (in shares) \| shares	4.6
Weighted-Average Grant-Date Fair Value
Unvested beginning balance (usd per share) \| $ / shares	$ 207.37
Granted (usd per share) \| $ / shares	283.62
Vested (usd per share) \| $ / shares	187.45
Forfeited (usd per share) \| $ / shares	230.38
Unvested ending balance (usd per share) \| $ / shares	$ 242.33

SHARE-BASED COMPENSATION - Stoc

SHARE-BASED COMPENSATION - Stock-Based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	$ 127.3	$ 110.1	$ 248.7	$ 214.3
Income tax benefit	20.9	22.5	48.1	43.1
Share-based compensation expense after income taxes	106.4	87.6	200.6	171.2
Total cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	26.1	21.8	50.4	42.8
Total cost of sales \| Cost of sales–products
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	20.3	16.6	39	31.9
Total cost of sales \| Cost of sales–services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	5.8	5.2	11.4	10.9
Selling, general, and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	62.7	55.7	123	108.8
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	$ 38.5	$ 32.6	$ 75.3	$ 62.7

SHARE-BASED COMPENSATION - Sche

SHARE-BASED COMPENSATION - Schedule of Estimated Fair Value of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock Options
Stock Options
Risk-free interest rate	2.90%	0.80%	1.70%	0.70%
Expected term (in years)	3 years 3 months 18 days	4 years	3 years 4 months 24 days	4 years 3 months 18 days
Expected volatility (percent)	38%	27%	36%	33%
Weighted average fair value at grant date (usd per share)	$ 72.35	$ 63.65	$ 80.27	$ 69.96
Employee Stock Purchase Program [Abstract]
Risk-free interest rate	2.90%	0.80%	1.70%	0.70%
Expected term (in years)	3 years 3 months 18 days	4 years	3 years 4 months 24 days	4 years 3 months 18 days
Expected volatility (percent)	38%	27%	36%	33%
Weighted average fair value at grant date (usd per share)	$ 72.35	$ 63.65	$ 80.27	$ 69.96
ESPP
Stock Options
Risk-free interest rate	0%	0%	0.80%	0.10%
Expected term (in years)	0 years	0 years	1 year 2 months 12 days	1 year 2 months 12 days
Expected volatility (percent)	0%	0%	37%	35%
Weighted average fair value at grant date (usd per share)	$ 0	$ 0	$ 88.85	$ 74.39
Employee Stock Purchase Program [Abstract]
Risk-free interest rate	0%	0%	0.80%	0.10%
Expected term (in years)	0 years	0 years	1 year 2 months 12 days	1 year 2 months 12 days
Expected volatility (percent)	0%	0%	37%	35%
Weighted average fair value at grant date (usd per share)	$ 0	$ 0	$ 88.85	$ 74.39

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 93.3	$ 3.2	$ 126.3	$ 16.8
Income tax expense, percentage of pre-tax income	22.90%	0.60%	15.60%	1.70%
Excess tax benefits associated with employee equity plans	$ 9.3	$ 43.6	$ 62.3	$ 117
Excess tax benefits associated with employee equity plans (in percent)	2.30%	8.30%	7.70%	12%
Swiss
Operating Loss Carryforwards [Line Items]
Re-measurement of deferred tax assets		$ 66.4		$ 66.4

NET INCOME PER SHARE - Computat

NET INCOME PER SHARE - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net income attributable to Intuitive Surgical, Inc.	$ 307.8	$ 517.2	$ 673.4	$ 943.5
Denominator:
Weighted average shares outstanding used in basic calculation (in shares)	358.1	355.7	358.2	355
Add: dilutive effect of potential common shares (in shares)	5.8	9.2	7.1	9.5
Weighted average shares outstanding used in diluted calculation (in shares)	363.9	364.9	365.3	364.5
Net income per share attributable to Intuitive Surgical, Inc.:
Basic (in dollars per share)	$ 0.86	$ 1.45	$ 1.88	$ 2.66
Diluted (in dollars per share)	$ 0.85	$ 1.42	$ 1.84	$ 2.59

NET INCOME PER SHARE - Addition

NET INCOME PER SHARE - Additional Information (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Employee stock options excluded from computation of diluted net income per share	4.3	1.2	3.4	1.1